 
 
 
 
 
 
 
VC02 -[ADDRESS_1109859] -IN-HUMAN, STUDY  
EVALUATING THE SAFETY , TOLERABILITY , AND  
EFFICACY OF VC -02™ COMBINATION PRODUCT IN  
SUBJECTS WITH TYPE 1 DIABETES MELLITUS AND  
HYPOGLYCEMIA UNAWARENESS  
 
Version 8, Amendment 9  
18 May 2020  
 
ViaCyte Inc . 
[STUDY_ID_REMOVED]  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109860]-IN -HUMAN, STUDY 
EVALUATING THE SAFET Y, TOLERABILITY, AND  
EFFICACY OF VC-02™ COMBINATION PRODUCT  IN 
SUBJECTS WITH TYPE 1 DIABETES MELLITUS A ND 
HYPOGLYCEMIA UNAWARE NESS  
 
 
 
Protocol Number  VC0 2-101 
Compound  PEC-01™ cells in a Delivery Device  (together 
known as VC -02 combination product ) 
Study Phase  1/[ADDRESS_1109861]. 
San Diego, CA [ZIP_CODE]  
Version Number  8.0 (Amendment # 9) 
 
 
  

ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
2 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  TABLE OF CONTENTS  
PROTOCOL SUMMARY  ...............................................................................................................7  
INVESTIGATOR’S AGREE MENT  .............................................................................................[ADDRESS_1109862] & STUDY INTERVENTIONS  .........................40  
5.1. VC-02™ Combination Product Description ................................................................[ADDRESS_1109863] to Site ...............................................................41  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109864] Storage, Stability, and Accountability ...........................................................41  
5.1.4.  Dosage and Administration ........................................................................................42  
5.2. Immunosuppression Medications  ...............................................................................44  
5.3. Other Concomitant Medications and Treatments .......................................................45  
5.4. Lifestyle Guidelines ....................................................................................................46  
5.4.1.  Dietary Restrictions  ....................................................................................................46  
5.4.2.  Exogenous Insulin Treatment and A dministration  .....................................................46  
5.4.3.  Physical Activity  .........................................................................................................47  
5.4.4.  Alcohol, Caffeine and Tobacco  ..................................................................................47  
5.4.5.  Contraception ..............................................................................................................47  
[IP_ADDRESS].  Women of Non-childbearing Potential .......................................................................48  
5.4.6.  Other Restrictions  .......................................................................................................48  
6. STUDY SCHEDULE  .................................................................................................48  
6.1. Visit 1 / Screening (Week  -5 to Week  -4) ..................................................................49  
6.2. Visit 2 / Screening (Week  -4 to Week  -2) ..................................................................49  
6.3. Visit 3 / Enrollment and Implantation (Day  1) ...........................................................50  
6.4. Visit 4 (Day  2) ............................................................................................................51  
6.5. Visit 5 (Week  2) ..........................................................................................................51  
6.6. Visit 6 (Week  4) ..........................................................................................................51  
6.7. Visit 7 (Week  8) ..........................................................................................................52  
6.8. Visit 8 (Week  12) ........................................................................................................52  
6.9. Visit 9 (Week  16) ........................................................................................................53  
6.10.  Visit 10 (Week 20) ......................................................................................................53  
6.11.  Visits 11 and 13 (Weeks 26 and 52) ...........................................................................54  
6.12.  Visit 12 (Week 39) ......................................................................................................55  
6.13.  Visits 14 and 16 (Weeks 65 and 91) ...........................................................................55  
6.14.  Visit 15 (Week 78) ......................................................................................................56  
6.15.  Visit 17 / Study Completion (Week 104) or Early Termination ................................56  
6.16.  Follow- up Visit  18 (Week 105) ..................................................................................57  
6.17.  Unplanned or Unscheduled Visits  ..............................................................................57  
7. STUDY ASSESSMENTS ..........................................................................................58  
7.1. Clinical Evaluations  ....................................................................................................58  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
4 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  7.1.1.  Physica l Examination  .................................................................................................58  
7.1.2.  Body Weight ...............................................................................................................59  
7.1.3.  12-lead ECG  ...............................................................................................................59  
7.1.4.  Vitals:  Sitting Blood Pressure, Pulse Rate, and Temperature  ...................................[ADDRESS_1109865] (MMTT)  ........................................................................[ADDRESS_1109866] (SOGCT ) ...................................................[ADDRESS_1109867]-Implant Discharge Instructions and Assessments  ..............................................61  
7.5. Photographs of Implantation and Explantation Sites ..................................................62  
7.6. Video of Implantation and Explantation Procedures ..................................................62  
7.7. Ultrasound Monitoring  ...............................................................................................62  
7.8. Explantation of VC-02™ Combination Product ........................................................63  
7.8.1.  Explantation of VC -02-20™ Sentinel Units ...............................................................64  
7.8.2.  Explantation of VC-02-300™ Units  ............................................................................[ADDRESS_1109868]  .........................................64  
7.10.  Blood Glucose Monitoring .........................................................................................65  
7.10.1.  Study Diary .................................................................................................................66  
7.10.2.  Continuous Glucose Monitoring (CGM) ....................................................................66  
7.10.3.  Self-monitoring Blood Glucose (SMBG) ...................................................................67  
7.10.4.  Definition, Classification, and Management of Hypoglycemic Events (HEs) ...........67  
7.11.  Laboratory Evaluations  ...............................................................................................68  
7.11.1.  Routine Clinical Laboratory Evaluations ...................................................................68  
7.11.2.  Pregnancy Tests  ..........................................................................................................69  
7.11.3.  Immunosuppression Drug Levels and Sa fety Labs ....................................................69  
7.11.4.  Immune Panel  .............................................................................................................69  
7.11.5.  Reserve Blood Samples  ..............................................................................................70  
7.11.6.  Blood Volumes ...........................................................................................................70  
7.12.  Clarke Survey  .............................................................................................................70  
8. SAFETY REPORTING  ..............................................................................................71  
8.1. Adverse Events ...........................................................................................................71  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109869] ( AESI)  ................................................................73  
8.1.5.  Period of Observation and Reporting .........................................................................74  
8.2. Serious Adverse Events (SAE)  ...................................................................................74  
8.2.1.  Suspected, Unexpected Serious Adverse Reactions (S[LOCATION_003]R)  ..................................[ADDRESS_1109870] (DSMB)  .....................................................................[ADDRESS_1109871] Characteristics ..................................................................81  
10.4.3.  Primary Safety Analysis  .............................................................................................81  
10.4.4.  Primary Efficacy Analysis  ..........................................................................................82  
10.4.5.  Secondary Analyses  ....................................................................................................82  
[IP_ADDRESS].  Secondary Efficacy Analyses  .....................................................................................82  
[IP_ADDRESS].  Secondary Safety Analyses .........................................................................................83  
11. SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA / DOCUMENTS  ...........................................................................................................83
 
12. SPONSOR AUDITS AND I NSPECTIONS BY [CONTACT_804151]  .................................................................................................................83  
13. ETHICS/PROTECTION OF HUMAN SUBJECTS  ..................................................[ADDRESS_1109872]  ..........................................................................................................84  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
6 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  13.2.  Ethics Committees  ......................................................................................................84  
13.3.  Informed Consent Process ..........................................................................................84  
13.4.  Exclusion of Women, Minorities, and Children (Special Populations) ......................[ADDRESS_1109873] OF TABLES  
Table 1.  SCHEDULE OF ASSESSMENTS  .............................................................................16  
Table 2.  VC-02 Dosing Projections (75 kg Human) ................................................................[ADDRESS_1109874] OF FIGURES  
Figure 1.  Cohort 1 Study Schematic ..........................................................................................35  
Figure 2.  Cohort 2 Study Schema tic ..........................................................................................37  
 
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
7 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  PROTOCOL SUMMARY  
Title: An Open -Label, First -in-Human, Study Evaluating the Safety, 
Tolerability, and Efficacy of VC- 02 Combination Product  in 
Subjects with Type 1 Diabetes Mellitus and Hypoglycemia 
Unawareness 
Phas e: 1/2 
Population:  Subjects with type 1 diabetes mellitus (T1DM) and 
hypoglycemia unawareness (HU) will be enrolled into this first-
in-human (FIH) clinical trial  
Cohort  1: At least three (3) subjects, but up to 15 total   
Cohort  2: Up to 60 subjects enrol led  
Total enrollment may be approximately 75 subj ects 
Number of Sites:  Approximately ten  (10) 
Study Duration:  The total duration of the trial is estimated to be up to 66 months:   
• Up to 42 months to complete enrollment of both cohorts  
• An additional [ADDRESS_1109875] Participation 
Duration:  Including Screening, Treatment, and Follow -up Visits, each 
subject’s duration of participation is estimated a s 110 weeks  
total (approximately two years).  
After all VC -[ADDRESS_1109876] will be 
required to be followed in a separate, long -term, follow -up 
study.  
Description of Agent or Intervention: ViaCyte has developed the VC- [ADDRESS_1109877] 
components: (1) PEC -01 pancreatic endoderm cells derived 
from human embryonic stem cells (hESC) and (2) a durable, 
removable, Delivery Device ( DD) designed to deliver and retain 
cells at the local implant site.  
Followi ng subcutaneous implantation in anatomical locations 
involving the trunk or extremities, the VC -02 units are expected 
to vascularize adequately and the PEC -01 cells are expected to 
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109878] as  sentinel units; these are smaller units that will be 
explanted a t various time points and examined ex vivo.  
An immunosuppression regimen will be used to facilitate the 
engraftment and long- term function of implanted VC -02 units.  
The overall regimen may vary between subjects but may include 
the use of basiliximab, anti-thymocyte globulin (ATG), 
etanercept, sirolimus, tacrolimus, steroids and/or mycophenolate 
mofetil (MMF) .  Additional medication s can be prescribed by 
[CONTACT_804152] t he Sponsor.  
Study Design:  This will be an open- label, FI H, clinical trial in subjects with 
T1DM and HU.   
Two cohorts are planned for enrollment in this trial:  
Cohort  1 – Initial Safety and Tolerability :  Up to 15 subjects may 
be implanted with up to two (2) VC -02-300 units and up to six 
(6) VC -02 sentinels at one (1) or more clinical sites .  If no VC -
02-[ADDRESS_1109879], up to ten (10) VC -[ADDRESS_1109880] three (3) subjects in Cohort  [ADDRESS_1109881].  If 
no serious, treatment -related adverse events (AEs) are observed 
with the first three (3) subjects after each has reached Week  2, 
subsequent Cohort  1 enrollment may be performed in parallel.  
Total duration of treatment (implantation) may be up to two (2) years  for each Cohort  [ADDRESS_1109882] unit explanted at 
Month 24. Cohort  1 subjects will complete a total of 18 study 
visits.  
After a minimum of three (3) subjects have been enrolled in 
Cohort  [ADDRESS_1109883] (DSMB) will review the cumulative Cohort  1 
data for safety, tolerability, and proof of mechanism.   
Cohort  2 – Up to [ADDRESS_1109884] a particular device con figur ation and/or implant strategy.  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109885] explants within a 
given cadre, the need for an alternate device configuration and/or 
surgical implant technique (e.g., pharmacological intervention, 
implant site, etc.) may be i dentified in order to improve 
engraftment and cell survival  outcomes . The se changes will be 
implemented prior to the next cadre of subjects commencing 
implantation to drive VC -02 engraftment optimization .   
Cohort 2 subjects will be implanted with up to twelve  (12) units.  
Of the twelve  implanted units, no more than ten (10) will be VC-
02-300 and the remainder will be VC- 02-20 units .  For example, 
if ten (10) VC-02-[ADDRESS_1109886], two  (2) 
VC-02 sentinels may be implanted.  Cohort  2 enrollment will be 
competitive across approximately  ten (10) sites.   Sentin el units 
may also be explanted at various time points post -implant .  
Total duration of treatment may be up to two (2) years for each Cohort  
[ADDRESS_1109887] unit explanted at Month 24. 
Cohort  2 subjects will complete a total of up to 18 study visit s.  
Study Objectives:  Objectives:  This trial will test whether VC- [ADDRESS_1109888]  can be implanted and maintained with safety, 
tolerability and efficacy for up to two years.  There are t wo 
cohorts in this FIH trial with the following study objecti ves. 
Cohort  1 study objectives:  
• Assess the local and systemic safety and tolerability of 
VC-[ADDRESS_1109889]  when implanted into subjects 
with T1DM and HU.   
• Assess histological proof of mechanism for VC -[ADDRESS_1109890] (e.g., cell survival an d different iation 
to beta cells).   
Cohort  2 study objectives:  
• Evaluate the clinical efficacy and further assess safety and tolerability of VC -
[ADDRESS_1109891] from 
implantation to Month 24. 
• Explore effects of weight, gender, BMI, or other potentiall y 
interacting factors on the responsiveness of the subjects to the experimental intervention.  
Exploratory  objectives : 
• Optimize the recommended surgical implantation procedure, anatomical location, and perioperative care for VC -02.  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
10 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Assess the effects of t he host immune response to implanted 
VC-02 units  
Primary Endpoints:  The primary endpoints vary between the two (2) c ohorts and 
include safety, tolerability, and efficacy. 
• Cohort  1: Targeted safety and tolerability profile inclusive 
of: 
o The incidence of AE s with causality related to VC -
[ADDRESS_1109892], the surgical procedures 
required for VC -02 administration, and the 
immunosuppressive drug regimen.  
o The incidence of off -target growth as evidenced by 
[CONTACT_804153] -02 units via lumen ultrasound 
measurem ents, or by [CONTACT_804154].  
o The incidence of immune sensitization defined by 
[CONTACT_804155] -HLA antibodies absent prior 
to implant.  
o Implant tolerability assessments (e.g., fever, 
erythema, pain, tenderness, induration) for up to  four 
hours post -implantation and at subsequent visits.  
• Cohort  2: Change from baseline to  Week  [ADDRESS_1109893] (MMTT)  
Secondary Endpoints:  Safety and Tolerability : Comprehensive profile of VC -[ADDRESS_1109894]  implanted for up to two years as measured 
by: 
• All reported AEs  
• The incidence of immune sensitization defined by [CONTACT_804156] -HLA antibodies absent prior to implant  
• Implant tolerability assessments (e.g., fever, erythema, pain, 
tenderness,  induration) for up to four hours post -
implantation and at subsequent visits  
• The incidence of subjects requiring a premature explant due to safety, tolerability, or malfunction issues  
Efficacy : 
• Change from baseline to Weeks 16, 26, 39, 52, 78, a nd 104 
in average daily insulin dose in the seven days preceding 
the Clinic Visit  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
11 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Percent of subjects who achieve a 50% reduction in average 
weekly exogenous insulin dose from baseline to  Weeks 16, 
20, 26, 39, 52, 78, and 104 
• Percent of subjects who achiev e exogenous  insulin 
independence; of those subjects achieving insulin 
independence, the percent achieving HbA1c <7.0%  
• Percent of time spent with blood glucose values at various 
cut points (e.g., <54 mg/dL, ≥54 to <70 mg/dL, ≥70 mg/dL 
to ≤180 mg/dL , and > 180 mg/dL ) as measured by [CONTACT_12072]’s continuous glucose monitoring (CGM) device  
• Change from baseline to Weeks 16, 26, 39, 52, 78, and 104 in time -in-euglycemic range  (≥70 mg/dL to ≤ 180 mg/dL ), 
time-in-hypoglycemic range s (<54 mg/dL and ≥54 to 
<70 mg/dL ), and time -in-hyperglycemic range s 
(>180 mg /dL) as measured by [CONTACT_6992]’s CGM 
Exploratory Endpoint:  Histological results of explanted units and any associated tissue 
capsule as evaluated for cell viabil ity, vascularization, immune 
response, an d/or cell maturation and differentiation.  
Inclusion Criteria:  • Signed and dated informed consent form  
• Men and non -pregnant women of 18- 65 years of age  
• Diagnosis of T1DM for a minimum of five (5) years  
• At least one severe hypoglycemic event , or for patients with 
CGMs, do cumentation of a low blood glucose value  <54 
mg/dL (<3.0 mmol/L), in the previous 12 months  
• Documented hypoglycemia unawareness (Clarke score ≥4) 
or significant glycemic lability  
as assessed by [CONTACT_3786]   
• Stable, optimized diabetic regimen for at least 3 months  
• Insulin dosage at screening <1 unit/kg/day  
• Willing to use a  provided CGM System  
• Willing and able to comply with daily entries on a study 
diary  
• All male subjects and female subjects of childbearing 
potential must practice effective contraception during the 
study and be willing and able to continue contraception until 
final explant. For further details of contraceptive 
requirements fo r this study, please refer to Sectio n 5.4.5 
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
12 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Exclusion Criteria:  • A detectable stimulated serum C -peptide at any time -point 
during the Screening period, defined as >0.2 ng/mL 
(>0.0667 nmo l/L) 
• Use of any oral diabetes -specific medication  
• Medical history of islet cell, kidney, and/or pancreas 
transplant  
• Occurrence of six or more severe, unexplained 
hypoglycemic events within six months of enrollment  
• Uncontrolled or untreated thyroid disease or adrenal  
insufficiency  
• Known causes of diabetes other than T1DM  
• Diabetic complications such as severe kidney disease or 
renal dysfunction, proliferative retinopathy, diabetic foot 
ulcers, amputations attributable to diabetes, and/or seve re 
peripheral neuropathy  
• Non-compliance wit h current anti -diabetic regimen  
• Hemoglobin A1C level of > 10.0%  
• Significant skin conditions involving the area(s) targeted for 
implantation  
• Alcohol abuse  
• Positive urine drug screen for substances of abuse at 
screening or enrollment visit, medical marijuana  use may be 
allowed by [CONTACT_978] [INVESTIGATOR_804125]/or Sponsor  
• Prior history of malignancy with the exception of:  
o Basal cell carcinoma of the skin;  
o Squamous cell carcinoma of the skin that has been recurrence free for ≥five years;  
o Appropriately treated in situ carcinoma of the cervix 
 
• Known a llergies to portions of the cellular excipi[INVESTIGATOR_804126] -01 manufacturing 
process (i.e., bovine, porcine allergies)  
• History of severe asthma or COPD  
• BMI ≥3 2 kg/m2 or <18 kg/m2 at screening  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
13 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Active hepatobiliary disease o r an AST or ALT >1.[ADDRESS_1109895] 
at screening or a total bilirubin >1.[ADDRESS_1109896] 
has a history of Gilbert’s disease  
• Active infection or known history of Hepatitis B or C or HIV  
• Evidence of previous TB infection (including BCG 
vaccination or posit ive [COMPANY_003])  
• Negative serostatus for Epstein -Barr virus  
• Other abnormal labs at screening:  
o Platelets <100,000 
o Hgb <12 g/dL (males) or <11 g/dL (females)  
o Fasting triglycerides >500  mg/dL 
o Estimated Glomerular Filtration Rate (GFR) 
<60 mL /min/1.73 m2 (using MDRD c alculator)  
• Clinical lab value outside normal range, unless deemed as not clinically significant by [CONTACT_10552]  
• 
Sustained hypertension defined as average systolic 
≥160 mmHg or diastolic ≥90 mmHg at screening  
• 12-lead ECG findings demonstrating:  
o QTc>450 msec for males or >470 msec for females 
at screening  
o Any other abnormality deemed clinically signif icant 
requiring further clinical evaluation by [CONTACT_3786]  
• Any history of unstable angina or Class 3 or 4 CHF, or any of the following diagnoses/conditions or procedures within the past year: stroke, myocardial infarction, life -threatening 
arrhythmia,  
major cardiovascular procedure (e.g., 
angioplasty, planned angioplasty, or carotid 
endarterectomy), or any other clinically significa nt 
cardiovascular disease diagnosis or procedure  
• History of coagulopathy  
• Participation in a study of an investigational drug, device, or 
graft within five half- lives of the experimental agent or 30 
days prior to enrollment in this study, whichever is longe r 
• Planned surgery in the general location of the implanted 
units (i.e., back and/or flank, arms, legs, abdomen, etc.) at 
any time during study participation  
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
14 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Statistical Considerations  Sample Sizes – Cohorts 1 and Cohort 2 
• Sample size in Cohort 1 was empi[INVESTIGATOR_68151], based upon 
safety considerations and data accumulated from previously 
performed ViaCyte clinical trials. A  sample size of up to 15 
subjects should allow for adequate assessment of Cohort 1 
study objectives. 
• A sample size of 60 subjects in Cohort 2 will enable 
staggered enrollment of cadres of subjects allowing for 
testing of alternate device configuration s and /or surgical 
implant technique (e.g., pharmacological intervention, 
implant site, etc.) in order to i mprove engraftment and cell 
survival outcomes. This approach will drive VC -02 
engraftment optimization.  
Sample Size – Primary Efficacy Endpoint  
• Once the op timized device configuration and surgical 
implant technique is determined, a  sample size of 40 subjec ts 
implanted  
 
 
   
If th
e minimal level of detection for C -peptide is 0.20 ng/mL, 
this would give an AUC of 0.8 ng x hour/mL for the 4-hour 
MMTT. A sample size of 40 subjects  
 
  
 
For the 2 -hour MMTT, a sample size of 40 subjects  
 
  
 
 
A
nalysis Populations 
• The Full Analysis Set (FAS) is defined as Cohort [ADDRESS_1109897] one VC -02 unit on Study Day  1. All efficacy 
summaries/analyses will be performed on the FA S.  
Subjects will be summarized by [CONTACT_1570].  
• The Safety Analysis Set (SAS) will include all Cohort 1 
and Cohort  2 subjects enrolled into the study and in whom 

ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
15 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  an implant surger y was att empted, regardless if any VC -02 
units were actually implanted.   
Primary Safety  
• The SAS will be used for the primary safety 
summarizations. Adverse events and SAEs will be 
summarized by [CONTACT_9313] ( SOC ), by [CONTACT_926], and 
by [CONTACT_2073]. T his will be done by [CONTACT_14459].   
• The summarization of AEs will focus on only those events 
that are TEAEs, but the AE listings will include all reported AEs regardless of when they started.   
• Other safety data, such as vital signs and clin ical laboratory 
data will be summarized by [CONTACT_804157].  
Where appropriate, change from baseline in safety data will 
also be summarized in a similar manner.   
• The number of subjects undergoing a premature VC -02-300 
unit explant will be provided in a listing which includes the reason for explantation.  
Primary Efficacy  
• Change from baseline to Week  26 in C -peptide AUC
0-4h 
following an MMTT will be analyzed using analysis of 
covariance (ANCOVA), with treatment group as a factor and baseline C -peptide AUC
0-4h as a covariate. The FAS 
will be used to analyze the pr imary efficacy endpoint. The 
output from the ANCOVA will include the least squares mean (LSM) and standard error (SE) for each treatment 
group. 
ViaCyte Inc.,  Confidential                    Amendment # 9 – Version 8.0 
Protocol #VC02 -101        18 MA Y 2020 
16 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Table 1. SCHEDULE OF ASSESSMENTS  
 V1 a 
Screen  V2 
Screen  V3 
Enroll  V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 
or 
ET V18 
Follow -
Up 
Assessments  Wk -5 Wk -4 Day 1 Day 
2 Wk 2  Wk 4  Wk 
8 Wk 
12 Wk 
16 Wk 
20 Wk 
26 Wk 
39 Wk 
52 Wk 
65 Wk 
78 Wk 
91 Wk 
104 Wk 
105 
Visit Window s  +14d   +1d +/- 
2d +/-3d +/-
7d +/- 
7d +/-
7d +/-
7d +/-
7d +/-
14d +/-
14d +/-
14d +/-
14d +/-
14d +/-
7d +/- 
3d 
Informed Consent  X                  
Entry Criteria  X X X                
Med History / Prior Meds  X                  
12-lead ECG  X          X  X    X  
Physical Exam (Complete ) X          X  X    X  
Physical Exam 
(Abbreviated)    X  X X  X    X   X    
Physical Exam (Targeted)     X              X 
Height  X                  
Weight / Vitals  X X X X X X X X X X X X X X X X X X 
Clarke Survey  X        X  X X X  X  X  
Immunosuppression Drug 
Dosing   X (adjust dosing as needed)  
Dispense / Review CGM 
Data   X X X X X X X X X X X X X X X X  
Dispense / Review Diary Data   X X X X X X X X X X X X X X X X  
Dispense / Review SMBG 
Supplies   X X X X X X X X X X X X X X X X  
Implantation Procedure    X                 
Explantation Procedure      X (time -points as determined by [CONTACT_2728]) X  
ViaCyte Inc.,  Confidential                    Amendment # 9 – Version 8.0 
Protocol #VC02 -101        18 MA Y 2020 
17 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared   V1 a 
Screen  V2 
Screen  V3 
Enroll  V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 
or 
ET V18 
Follow -
Up 
Assessments  Wk -5 Wk -4 Day 1 Day 
2 Wk 2  Wk 4  Wk 
8 Wk 
12 Wk 
16 Wk 
20 Wk 
26 Wk 
39 Wk 
52 Wk 
65 Wk 
78 Wk 
91 Wk 
104 Wk 
105 
Ultrasound - Safety 
Evaluation        X  X  X  X  X  X  
Ultrasound - Pre-Explanta      X (time -points TBD based on explant pro cedures)  X  
Video and Photosb   X X (additional time -points TBD based on explant procedures) X  
AE and Concomitant 
Medications   X X X X X X X X X X X X X X X X X 
ICD for Follow -Up Studyc                 X 
Central Laboratory Tests or Study -Provided Test ing Kits  
Drug Screend X  X                
HBsAg, HCV, HIV  X                  
CMV IgG and IgMg  X           X    X  
CMV PCR   X      X   X        
EBV  IgG X                  
Hematology & Chemistry  X X X  X X X X X X X X X X X X X  
HbA1c  X  X      X  X  X  X  X  
Follicular Stimulating 
Hormone  X                  
Urine Pregnancy Teste X  X          X    X  
Thyroid Stimulating Hormone
f X                  
Quantiferon TB  X                  
SOGCT C -peptide  X                  
Ultrasensitive C -peptideh   X     X X X X X X X      
ViaCyte Inc.,  Confidential                    Amendment # 9 – Version 8.0 
Protocol #VC02 -101        18 MA Y 2020 
18 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared   V1 a 
Screen  V2 
Screen  V3 
Enroll  V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 
or 
ET V18 
Follow -
Up 
Assessments  Wk -5 Wk -4 Day 1 Day 
2 Wk 2  Wk 4  Wk 
8 Wk 
12 Wk 
16 Wk 
20 Wk 
26 Wk 
39 Wk 
52 Wk 
65 Wk 
78 Wk 
91 Wk 
104 Wk 
105 
2-hr MMTT/C -peptide & 
Glucose        X X X X  X  X  X   
4-hr MMTT/C -peptide & 
Glucose   X         X  X  X  X  
Urinalysis  X                  
Urine Albumin/Creatinine   X         X  X  X  X  
Fasting Lipid Panel  X          X  X    X  
Immune Panel   X    X   X  X  X    X  
Reserve Blood Samples  X          X  X  X  X  
Local Laboratory Tests  
Immunosuppression Drug 
Levels  & Safety Panels     X (frequency as described in Section  7.11.3 ) 
a. Pre-explant unit location ultrasound only required at the discretion of the Investigator.  Unit location may be determined via pa lpation 
depending on anatomical location ( Section  7.7). 
b. Video and/or photographs of  the surgical procedure or implantation anatomical locations are to be captured only if requested by [CONTACT_804158].  
c. A separate cons ent document will be provided to the subject for the follow -up study.  
d. The Visit  [ADDRESS_1109898] -menopausal women  who are not using contraception.  
g. CMV IgM is not tested at Visit 2 (only IgG).  CMV IgG and IgM testing is performed at Visit [ADDRESS_1109899] results 
were negative.  
h. Ultrasensitive C -peptide samples to be collected in conjunction with MMTTs pre -stimulation  (time = 0)  and post -stimulation at the 90 -minute (+/- 10 minutes ) timepoint . 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
19 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  INVESTIGATOR’S AGREE MENT  
 
 
By [CONTACT_12570], I confirm that I have read and agree to conduct the trial as outlined 
herein, complying with the obligations and requirements of clinical investigators and all other requirements listed in the Code of  Federal Regulations.  
 
 
       
Principal Investigator’s Name (printed)   
 
 
             
Principal Investigator’s Signature    [CONTACT_804213].,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109900] to critical review and has been approved by [CONTACT_456].  
The information it contains is consistent with:  
• The current risk -benefit evaluation of the investigational product  
• The moral, ethical, and scientific princip les governing clinical research as set out in the 
Declaration of Helsinki and the principles of GCP as described in the Code of Federal Regulations and according to applicable local requirements.  
The investigator will be supplied with details of any significant or new findings, including adverse events, relating to treatment with the investigational prod uct.  
 
 
   May 18, [ADDRESS_1109901] Foyt, MD, PhD, FACP    Date  
Vice President, Clinical Development  
Chief Medical Officer  
  

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
21 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  REVISION HISTORY  
Version Number  Version Date  
1.0 08 November 2016 ( Original) *never implemented  
1.1 01 March 2017 (Amendment #1 – [LOCATION_002] Only) *never 
implemented  
1.2 15 March 2017 (Amendment #2 – [LOCATION_002] Only)  
2.0 31 July 2017 (Amendment #3 – [LOCATION_002] Only ) 
3.0 17 October 2017 (Amendment #4 – [LOCATION_002] Only ) 
4.0 29 November 2017 (Amendment #5 – Canada Only)  
5.0 24 July 201 8 (Amendment #6)  
6.0 11 October 2019 (Amendment #7)  
7.0 18 March 2020 (Amendment #8 – Belgium Only ) 
8.0 18 May 2020 (Amendment #9)  
 
  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109902] 
EBV  Epstein -Barr Viru s 
EC Ethics Committee  
ECG  Electrocardiogram  
EDDS  Encaptra® Drug Delivery System  
EIU Exposure in Utero  
EoP2  End of Phase [ADDRESS_1109903]-in-Human  
FSH Follicular Stimulating Hormone  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109904]  
MRI  Magnetic Resonance Imaging  
NCI-CTCAE  
 National Cancer Institute Common Terminology Criteria for Adverse 
Events  
DD Delivery Device  
PE Physical Exam  
PEC Pancreatic Endoderm Cells  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109905]  
VC-02 VC-02™ Combination Product  
VLDL  Very Low -Density Lipoprotein  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109906] solut ion. The natural history of type 1 diabetes mellitus 
(T1DM) presents acute an d chronic health risks to all affected patients. Controlling the disease 
with insulin self -administration carries the acute risk of hypoglycem ic events (HE)  and even death, 
and the need for constant vigilance and testing results in a significant degradatio n of quality of life 
for the patient (and often, their families). Moreover, controlling the short -term challenges of 
diabetes with monitoring and insulin does not prevent the seri ous long- term sequelae of diabetes.  
These long -term sequelae include microva scular complications, such as peripheral and autonomic 
neuropathies, nephropathies, retinopathy, and diminished wound healing, as well as macrovascular complications and cardiovascular disease.  
Certain subgroups of T1DM patients have increased risks associ ated with hypoglycemia due to 
the relative absence of physiological symptoms associated with low blood glucose, also known as hypoglycemia unawareness  (HU).  Additionally, subgroups of patients who experience wide 
swings in blood glucose levels also are at particular risk of severe hypoglycemia. It has been reported that as many as 10% of patients with T1DM fall into this high -risk category ( Ryan, et al.,  
2004) .  Further, as many as 50% of insulin- dependent diabetes mellitus pat ients at [ADDRESS_1109907] their ability to perceive the autonomic symptoms associated with 
low blood sugar.  Severe hypoglycemia has been reported to occur six to seven  times more 
frequently in patients with this reduced awa reness (Gold, Macleod, & Frier, 1994). Thus, despi[INVESTIGATOR_804127] -of-care for T1DM, as well as for 
many insulin- requiring patients with advanced  type 2 diabetes mellitus (T2DM) a nd beta cell 
exhaustion, significant quality of life issues, co- morbidities, and an elevated risk of mortality 
remain challenges with the disease. Indeed, an enormous unmet need e xists among millions of 
insulin -dependent diabetic patients.   
As the primary  pathogenesis of T1DM is loss of insulin- producing pancreatic beta cell mass, it is 
an ideal candidate for cell replacement therapy.  Transplantation of cadaveric islets has proven  to 
be an effective treatment for this high -risk patient population, resulting in insulin independence in 
the majority of treated patients.  While cadaver islet transplant requires immunosuppression, which 
carries certain health risks, the therapy has demo nstrated an appropriate risk- benefit ratio in these 
patients  (CITR Coordinating Center, 2011).   
Islet replacement can control blood glucose in a more biological and homeostatic manner than injectable pharmaceuticals, including  the various forms of insulin currently on the market, thus 
reducing or eliminating the blood glucose excursion extremes that plague current therapy. In 
addition, by [CONTACT_1541] a more physiologic form of insulin (i.e., pro- insulin, as opposed to 
exogenous i nsulin injections), this treatment would also restore C -pepti de, which has been reported 
to alleviate and/or prevent diabetic microvascular complications, such as neuropathy and 
nephropathy ( Wahren, Kallas, & Simas, 2012). If fo und to be safe and effective, an islet 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109908] ma y prevent not only the short -term dangers of glycemic excursions, which 
can result in severe  hypoglycemic events  (SHE)  and diabetic ketoacidosis, but also the long- term 
effects of the disease and  current treatments.  In addition, islet replacement therapy has the 
potential to vastly improve the quality of life for patients with T1D M.   
While clinical proof- of-concept of the benefits of islet replacement has already been demonstrated 
through alloge neic isle t transplantation (Barton, et  al., 2012) , one of the substantial limitations 
reported for cadaver islet transplant is a lack of suitable donor islets.  Derivation of pancreatic 
lineage cells from human embryonic stem ce lls (hESC)  has been a major focus of research as a 
means to p roduce islets for transplantation.  Directed differentiation of hESC has the potential to 
result in a cell product that is predisposed to continue differentiation down the pancreatic lineage, 
and to mature into pancreatic endocrine hormone -producing cells, including glucose -responsive, 
insulin -producing cells, following implantation in vivo.  Lastly , the islet transplantation field has 
long sought alternatives to the intra -portal transplantation s ite associated with cadaveric islet 
transplantation ( Cantarelli & Pi[INVESTIGATOR_77878], 2011 ). 
1.2. Investigational Product 
ViaCyte, Inc. is developi[INVESTIGATOR_804128], especially T1D M. A 
central focus of ViaCyte’s overall strategy is utilization of a candidate somatic cell therapy 
comprised of pancreatic endoderm cells ( PEC-01) differentiated from hESC  that in nonclinical 
studies mature into pancreatic endocrine hormone -producing cells, including glucose -responsive, 
insulin -producing cells  following subcutaneous implantation.  The direct use of PEC -[ADDRESS_1109909] (VC -02), is comprised of PE C-01 
loaded in a Delivery  Device (DD) with a  membrane containing holes of controlled diameter and 
density designed to deliver and retain cells at the local implant site. The DD provides a means for  
maintaining the acute cell survival benefit provided by [CONTACT_804159]. The holes will be large enough to allow capi[INVESTIGATOR_804129], 
yet provide substantial retention of the cell product and thus facilitate formulation, delivery, and 
ultimate retr ieval of  the cells through explant of the combination product including the device and 
associated tissue capsule.  
Delivery of PEC -[ADDRESS_1109910] efficacy in athymic nude rats whereas fully -encapsulated delivery (no holes ) 
of PEC-[ADDRESS_1109911] that delivery of PEC -01 
in this format may perform robustly as a result of (1) the direct vascularization of the implanted cells allowing for intimate transport of oxygen and nutrients  and (2) a substantially reduced impact 
of the body’s innate foreign body giant cell (FBGC) response. T he formation of a layer of FBGC 
with cell processes that extend across a device membrane can impede transport of oxygen and 
nutrients leading to poor cell function and even cell death (Brauker, Shults, & Tapsak, 2004).  
Direct vascularization of the graft can overcome the negative impact of FBGC at the membrane 
ViaCyte Inc.,  Confidential   Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109912] vascularization accompanies graft maturation to provide a source for 
oxygen and other nutrients, and a mechanism to deliver insulin and other graft -expressed hormones 
to the body. The insulin- producing capability of VC -02 increases gradually; in nonclinical studies, 
the product reaches glucose- responsive activity as early as three to four months after implantation , 
with maximal regulation of host glycemia occurring at approximately nine months. 
Importantly, due to its stem cell -derived nature, VC-02 overcomes the limitations associated with 
use of deceased organ donors, which are principally: (1) severely limited supply of suitable 
cadaveric islets relative to th e demand, and (2) patient risks associated with donated organs (e.g., 
donor- derived pathogens). Moreover, the delivery device, subcutaneous implantation route , and 
use of PEC -01 provide several advantages over current clinical islet transplantation, includ ing: 
•The ability to non-invasively monitor and image the graft site with conventional imaging  
modalities;
•A single, subcutaneous implantation procedure with the potential of delivering therapeutic  
benefit equivalent in duration and ef ficacy to islet transplants which in comparison often 
require multiple infusion procedures;
•Subsequent explant of the grafted device, allowing for biopsy and histological evaluation;
•Elimination 
of portal thrombotic events;
•Decreased risk of the deleterious effects on islets associated  with instant blood mediated  
inflammatory reaction; and
•The potential for lower doses of required immunosuppressive drugs, thus decreasing the  
risk of adverse events, due to the hypo-immunogeneic nature of  PEC-01 (Drukker , et al. , 
2006 ). 
In summary, if the benefits of VC -02, as demonstrated in nonclinical studies, are realized in human 
trials, this product could deliver an essentially unlimited supply of robust and highly effective cells and could become a dramatically life -changing therapy for high- risk T1DM patients.    
1.3. Nonclinical Information  
In addition to the following sections, extensive nonclinical details on PEC -01, the DD, and VC -02 
are available in the Investigator Brochure (IB).  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109913] been subjected to a risk assessment and  meet acceptance 
criteria for Phase 1 clinical  manufacturing.  To ensure sufficient safety of PEC -01, Good 
Manufacturing Pra ctice ( GMP ) manufacturing of PEC -01 is performed in compliance with 
regulations and quality control procedures appropriate for the phase of clinical use.  
Characterizations of PEC -01 include assessment of identity, purity, quality, and stability. 
It should  be noted that the PEC -01 cells utilized in VC -02 represent the same drug substance tested 
extensively in nonclinical studies in support of the development of ViaCyte’s VC -[ADDRESS_1109914]. 
1.3.2. Nonclinical Evaluation of Safety of the Delivery Device  
Nonc linical evaluations of the Delivery Device component of VC -02 include a compi[INVESTIGATOR_804130]. Additionally, extensi ve 
studies were performed with ViaCyte’s Encaptra ® drug delivery system (EDDS ), which is  
analogous in design and materials to the DD except that it does not have holes in the membrane of 
the device . Testing performed has demonstrated that the DD  is capable of supporting survival, 
differentiation, and maturation of PEC -[ADDRESS_1109915] majority of rodents 
implanted  in these murine  studies were athymic nude rats, a model in which the FBGC response 
more closely mimics humans (relative to mice ). Of these studies, focused on the  
pharmacologic attributes of VC -02, resulting in the following observations: 
• Homeostatic, glucose -stimulated insulin secretion is evidenced by C-peptide production at 
levels sufficient to protect against hyperglycemia yet not induce hypoglycemia. 
• While different densities in the number of holes in a device result  in similar efficacy, an 
optimal configur ation protects implanted cells acutely after implantat ion while enabling 
host vascularization and ingress of host maintenance cells later in the engraftment process. 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
29 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • The efficacy of VC -[ADDRESS_1109916] use of an immunosuppression 
drug regimen. 
• Shelf -life stability (Section  5.1.3) for VC -[ADDRESS_1109917]-implant when stored in cell me dium for extended periods pre -implant .    
Two studies were conducted with primary focus on establishing the safety profile of VC -02 in the 
nonclinical setting. One GLP study was completed to assess tolerability, systemic toxicity, 
tumorigenicity, and cellular distribution. The second study further assessed cellular distribution, but al so the ab ility to explant all cells from the graft site through use of a luciferase -tagged PEC -01 
cell line. Key findings were as follows: 
• No indications of local implant site intolerability, systemic toxicity,  cellular distribution  
beyond the intended imp lant loca tion, or tumor formation  were observed .   
• Virtually all of the cellular content of the VC -[ADDRESS_1109918] explant  (≥ 99.9%) . Some limited PEC -01-derived cells can be found in host tissue 
surrounding the VC -[ADDRESS_1109919] from the implant 
site, instead remaining within the boundaries of the healed foreign body capsule.  
• There is n o evidence of systemic distribution of cells away from the implant site.  
Additional details on the design and result of nonclinical studies are available in the VC -[ADDRESS_1109920] demonstrates efficacy , the dosing 
requirement for exogenous insulin may decrease over time.  
1.4.1. Potential Risks  
Some of the  potential risks for study participation are hypothetical at this stage  of VC- 02 
development . There are saf ety-related, strictly -defined discontinuation  and explant rules noted in 
Section  8.5. Potential risks include, but are not limited to the below items.  
• There are inherent surgical  risks with  the implantation a nd explantation of VC- [ADDRESS_1109921] -procedure analgesia.  
• With an y implanted product, the possibility of migration or extrusion of the implant 
exists, along with the need for explantation.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
30 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • The use of anesthesia itself may cause side effects. The type(s) of anesthesia used during 
the implantation and explantation procedures will be determined by [CONTACT_941] I nvestigator or 
Surgeon.  Side effects may include, but are not limited to:  
− Local A nesthesia : Stinging and/or a  burning sensation . Less likely side eff ects include 
nausea, vomiting, dizziness, drowsiness, allergic reactions ( e.g., redness, itching, and 
rash), low blood pressure, weakness, severe numbness or tingling, ringing in ears, blurry or double vision, slurred speech, metallic taste in mouth, menta l status change, 
muscle twitching, and seizures.  
− General A nesthesia : Harm to the vocal cords, heart attack, lung infection, stroke, 
trauma to the teeth or tongue, or temporary mental confusion. Rarely, waking during anesthesia or death may occur.  
− Conscious Sedation :  Difficulty breathing.  
• After implant of VC-02, t here may be an increased risk  of HEs. Although the risk of HEs  
from grafted units is minimal based upon nonclinical results, as the implanted cells begin 
producing insulin, subjects and investigators need to monitor blood sugar levels closely and adjust the amount of req uired exogenous insulin.   
In addition to Investigator review of glucose trends, insulin dosing, and HE occurrenc es, the 
Sponsor will conduct routine reviews of blood glucose data. These data are collected as part of the required study procedures. S ubjects record insulin dosing and all HE occurrences on a study diary 
and glucometer data are electronically downloaded.  The data are then available in near real -time 
for review.  If potentially concerning trends are evidenced for an individual subject, the Spons or 
will notify the Investigator and follow -up with the subject will occur if necessary  (Section 7.10 – 
Blood Glucose Monitoring).   
• There is a risk VC-[ADDRESS_1109922] function of VC-02 is expected to exceed  the lifetime of animal models. The 
duration of exposure proposed f or this clinical trial is up to two years.   
• There is a risk of immune reactions and inflammatory responses due to the implantation of 
VC-02. The adjunct use of immunosuppressive drugs and anti -inflammatories, along with  
the design of the device , may  minimize/eliminate this risk.  
• The adjunct use of certain drugs may have side effects. The type(s) of medications used 
will be determined by [CONTACT_804160]. Side effects may include, but are not 
limited to:  
− Immunosuppressive Drugs:  Increased risk of  infection, cancer, loss of appetite, 
nausea, vomiting, increased hair growth, and hand tremors.   
− Anti-inflammatory Agents:  Stomach problems (e.g., pain, constipation, and diarrhea), 
kidney problems, anemia, dizziness, edema, abnormal liver tests, headaches, easy 
bruising, tinnitus, high blood pressure, and rash.    

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
31 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  − High -dose Steroids :  Allergic reactions, changes in emotions or mood, changes in 
vision, eye pain, infection, edema, and high blood sugar levels.     
• There are risks the implanted product may limit  the subject’s ability  to be a candidate for 
future islet cell transplantation  through sensitization. 
• There is a potential, hypothetical risk of off- target cell growth (e.g., teratomas). Ultrasound 
monitoring of the implanted units will occur throughout the trial.  
• There is the potential for VC -02 to rupture or break.  
 
 
However, the device will 
not prevent penetration by [CONTACT_804161] (e.g., insulin needle).   
• As human cells are being implanted, there is also a small risk that the subject could contract 
a disease or condition transmitted through the allogene ic cell line.  
1.4.2. Potential Benefits  
At this stage in  VC-02 clinical development , there are no known benefits. However, the re are 
several  potential benefits of this therapy as noted below.  
• Improved overall glycemic control  
• Reduction in exogenous insulin dos ing 
• Reduction in the number of insulin injections and/or complete elimination of exogenous insulin inje ctions 
• Reduction in the frequency of blood glucose monitoring 
• Reduction in the number of hypoglycemic events 
• Improvement in hypoglycemia awareness ( Leitao, et al., 2008 ) 
• Reduction in the risk of micro- and macro -vascular compli cations 
• Improvement in Quality of Life from an economic and lifestyle standpoint (e.g., decreased exogenous insulin requirements, fewer self -monitoring blood glucose  supplies , dietary 
freedom ) 
The allowe d number of VC -[ADDRESS_1109923] three to six  months, VC-02 
is expected  to vascularize adequately, and pa ncreatic progenitor cells are expected to differentiate 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109924] coh orts in this FIH trial, and the co horts serve different objectives. 
Cohort  1 Study Objective s: 
• Assess the local and systemic safety and tolerability of VC -[ADDRESS_1109925] s with T1DM and HU.  
• Assess histological proof of mechanism for VC -[ADDRESS_1109926] (e.g., cell survival 
and differentiation to beta cells).  
Cohort  2 Study Objective s:  
• Evaluate the clinical efficacy and further assess safety and tolerability of VC -[ADDRESS_1109927] from implantation to Month 24. 
• Explore effects of weight, gender , BMI, or other potentially interacting factors on the 
responsiveness of the subjects to the experi mental intervention.  
Exploratory  Objectives (Cohorts 1 & 2) : 
• Optimize the recommended surgical implantation procedure, an atomical location, and  
perioperative  care for VC -02. 
• Assess the effects of the host immune response to implanted VC -[ADDRESS_1109928] immune response, which includes both 
cohorts , as specified in  Section  2.2.3.  
2.2.1. Primary Endpoint  Measures  
Primary Endpoint  / Cohort  1: 
• Targeted safety and tolerability profile, inclusive of:  
− The incidence of AEs with cau sality related to VC -[ADDRESS_1109929], the 
surgical procedures required for VC -02 administration, and the immunosuppressive 
drug regimen. 
− The incidence of off -target growth as evidenced by [CONTACT_804153] -02 units via lumen 
ultrasound measurements, or by [CONTACT_804162].  
− The incidence of immune sensitization defined by [CONTACT_804155] -HLA 
antibodies absent prior to implant.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
33 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  − Implant tolerability assessments (e.g., fever, erythema, pain, tenderness, induration)  
for up to four hours post -implantation and at subsequent visits. 
Primary Endpoint  / Cohort  2: 
• Change from baseline to Week  26 in C -peptide AUC 0-4h following a n MMTT . 
2.2.2. Secondary Endpoint  Measures  
Secondary Safety  and Tolerability Endpoints : The c omprehensive safety profile of VC -[ADDRESS_1109930] implanted for up to two years as measured by:   
• All reported AEs  
• The incidence of immune sensitization defined by [CONTACT_804155] -HLA antibodies 
absent prior to implant.  
• Implant tolerability assessments (e.g., fev er, erythema, pain, tenderness, induration) for 
up to four hours post -implantation and at subsequent visits.  
• The incidence of subjects requiring a prem ature explant due to safety, tolerability, or 
malfunction issues.  
Secondary Efficacy Endpoints:  
• Change from baseline to Weeks 16, 26, 39, 52, 78, and 104 in C -peptide AUC 0-2h or 
AUC 0-4h following an MMTT;  
• Time to onset of biological response of C -peptide f ollowing MMTT;  
• Percent of subjects achieving a positive stimulated C -peptide (defined as >0.2 ng/mL) 
after implant;    
• Change from baseline to Weeks 16, 26, 39, 52, 78, 104 in weekly frequency of 
hypoglycemic events;  
• Percent of subjects free of severe hypog lycemic events from Week  16 to Weeks 20, 26, 
39, 52, 78, and 104;  
• Change from baseline to Weeks 16, 26, 39, 52, 78 and 104 in Clarke score;  
• Change from baseline to Weeks 16, 26, 39, 52, 78, and 104 in average daily insulin dose 
in the seven days preceding the Clinic  Visits ; 
• Percent of subjects who achieve a 50% reduction in average weekly exoge nous insulin 
dose from baseline to  Weeks 16, 20, 26, 39, 52, 78, and 104;  
• Percent of subjects who achieve exogenous insulin independence; of those subjects 
achieving insulin independence, the percent achieving HbA1c <7.0%  
• Percent of time spent with blood glucose values at various cut points (e.g., <54 mg/dL, 
≥54 to <70 mg/dL, ≥70 mg/dL to ≤ 180 mg/dL, and > 180 mg/dL ) as measured by [CONTACT_12072]’s CGM device.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
34 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Change from baseline to Weeks 16, 26, 39, 52, 78, and 104 in time- in-euglycemic range 
(≥70 mg/dL to ≤ 180 mg/dL), time- in-hypoglycemic range s (<54 mg/dL and ≥54 to 
<70 mg/dL ), and time -in-hyperglycemic range s (>180 mg/dL ) as measured by [CONTACT_12072]’s CGM 
2.2.3. Exploratory Endpoint Measures 
Exploratory Endpoint s/ Cohort 1 and 2 : 
• Histological results of expl anted units and any associated tissue capsule as evaluated for 
cell viability, vascularization, immune response, and/or cell maturation and 
differentiation.  
3. STUDY DESIGN  
This will be an open- label, FIH, clinical trial in subjects with T1DM and HU.  Two cohorts are 
planned for enrollment in this trial, with enrollment of Cohort [ADDRESS_1109931] up to 
eleven VC -02 units  implanted   
s deemed appropriate by [CONTACT_145033]/or S urgeon after  consultation with the Sponsor. Documentation of the implant 
plan for a subject will be provided to the Investigator by [CONTACT_1034].  
.  
At the end of the treatment period  for each subject , all remaining implanted units will be removed , 
and the subject will be required to participate in a separate, follow -up, non-interventional , 
observational study. The primary purpose of this additional study is to ensure there are no long -
term safety issues associated with previous implantation with VC-02. Each  Cohort is described in further detail below.  
3.1. Cohort [ADDRESS_1109932] in this study at one (1) or more  clinical sites. A minimum 
of 3 and up to 15 subjects may be enrolled in Cohort 1. Initially , up to ten (10)  VC-02- 20 units 
(sentinels ) will be implanted in Cohort [ADDRESS_1109933] three (3) subjects enrolled in Cohort [ADDRESS_1109934] three  
subjects are enrolled in Cohort 1, VC-02- 300 units may  then be implanted in subsequent subjects 
and the stimulated C -peptide levels will be monitored. These additional Cohort 1 subjects may be 
implanted with up to two (2) VC -02-300 units and up to six (6) VC -[ADDRESS_1109935] n and this 
number may be reduced . However, if no VC -02-300 units are implanted in these additional Cohort 
1 subjects, up to ten (10) VC-02 sentinels may instead be implanted.   

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
35 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  The t otal duration of treatment (implantation) may be up to two (2) years  for each Cohort  [ADDRESS_1109936] response. The VC- 02-300 unit(s) and all 
remaining sentinel unit s will be  explant ed at Visit 17/Week  104.  Including the requirements of 
the screening period, Cohort  1 subjects will complete a total of 18 study visits  spanning 
approximately 25 months  as outlined in Table 1 – Schedule of Assessments. At a minimum, the 
first three (3) subjects in Cohort  [ADDRESS_1109937] three (3) subjects after each has reached Week  4, additional  Cohort  1 
enrollment may then be performed in parallel.  
A target minimum of three (3 ) evaluable subjects will be enrolled  as part of Cohort  1, but up to 15 
total subjects may be enrolled in Cohort  1 if the Sponsor and/or Data Safety Monitoring Board 
(DSMB)  determine that additional subject data are necessary to properly evaluate the 
inves tigational product and/or the implantation procedure.  After the minimum of three (3) subjects 
have been enrolled in Cohort  [ADDRESS_1109938] the DSMB  to meet t o review the cumulative Cohort  1 
data for safety, tolerab ility, and proof of mechanism.  
The DSMB will not meet re gularly during Cohort  1 unless the Sponsor seeks an independent 
DSMB review based on Sponsor or Ethics Committee (EC ) recommendations for managing AE s.  
The DSMB chair and/or the entire DSMB  may receive regular updates as to the progress of the 
trial during Cohort  1. 
Figure 1.  Cohort  1 Study Schematic  
 
 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
36 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  3.2. Cohort 2 
Enrollment of Cohort 2 will include  up to 60 additional subjects who will be implanted with up to 
twelve  (12) units. Of the twelve  implanted units, no more than ten  (10) will be VC-02- 300 units , 
and the remainder will be VC-02-20 units . For example , if ten  (10) VC-02- 300 units are implanted, 
up to two  (2) VC-[ADDRESS_1109939] a particular device configuration and/or 
implant strategy. Based on information obtained from subjec t explants within a given cadre, the 
need for an alternate devi ce configuration and/or surgical implant technique (e.g., pha rmacological 
intervention, implant site, etc.) may be identified in order to improve engraftment and cell survival 
outcomes. These changes will be  implemented prior to the next cadre of subjects commencing 
implantation  to drive VC -02 engraftment optimization. 
Cohort 2 enrollment is competitive across approximately  ten (10) sites, inclusive of those 
participating in Cohort 1. The total duration of treatment may be up to two (2) years for each 
Cohort [ADDRESS_1109940] -implant. All 
remaining VC-02-300 and sentinel units will be explanted at Visit 17/ Week  104.  Including the 
requirements of the screening period, Cohort 2 subjects will complete a total of up to 18 study 
visits spanning approximately 25 months  as outlined in Table 1 – Schedule of Assessments. 
The number of VC -02-[ADDRESS_1109941] to discontinue exogenous insulin; 
 units may  be implanted in subjects, and the stimulated C -peptide levels will be monitored .  
However, if VC- 02 does not function as robustly in humans as observed in pre -clinical models, 
then the number of VC-02-300 units may increase  
 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109942] subjects for whom protocol treatment is considered appropriate. All 
relevant medical and non -medical conditions shoul d be taken into consideration when deciding 
whether this protocol is suitable for a particular subjec t. 
4.1. Number of Patients and Sites  
A minimum of three (3) and up to 15  subjects total will be enrolled in Cohort  1 at one (1) or more 
sites. Cohort  2 will enroll up to 60 subjects from approximately ten  (10) sites. Therefore, the total 
enrollment possible for the trial (Cohort  1 and Cohort  2) is up to [ADDRESS_1109943] eligibility should be reviewed and documented by [CONTACT_85810]’s trial team before subjects are included in the trial. Subjects must m eet all of the 
following criteria at the time of the screening period  (unless otherwise specif ied) to be eligible for 
enrollment into the trial.  If screening laboratory test result(s) exclude a subject and the investigator 
is reasonably certain the results may be due to a lab error or may have been flawed for another 
reason, the lab test(s) may be repeated once during the screening period without prior permission 
from the Sponsor or its designee.  
4.2.1. Inclusion Criteria  
The following inclusion criteria are appli cable to all subjects:  
1. Evidence of a personally signed and dated informed consent document (ICD) indicating the subject has been informe d of all aspects of the trial.  

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
38 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  2. Men and non -pregnant women 18- 65 years of age.  
3. Diagnosis of  T1DM for a minimum of five (5 ) years . 
4. Stable, optimized insulin  regimen for at least 3 months .  Variations in the dose of insulin are 
permitted and can still meet the definition of stable  insulin dose ( refer to the s tudy reference 
manual for additional guidance on acceptable variations ).  Subject should be  under the care of 
a physician using intensive insulin therapy with therapeutic goals consistent with standard of 
practice (e.g., American Diabetes Association guidelines) for a minimum of 6 months.  
5. Insulin dosage at screening <1 unit /kg/d ay (using previous seven days as average) . 
6. The subject is an acceptable candidate for implantation and explantation of VC-[ADDRESS_1109944] -surgical care and 
restrictions, laboratory tests, fingerstick blood glucose monitorin g, and other study procedures. 
10. Documented hypoglycemia unawareness (Clarke score ≥4) or significant glycemic lability as 
assessed by [CONTACT_737].   
11. At least one severe hypoglycemic event , or for patients with CGMs, documentation of a low 
blood glucose value <54 mg/dL (<3.0 mmol/L), in  the previous [ADDRESS_1109945] practice effective 
contracept ion during the study and be willing and able to continue contraception until final 
explant .  For further details of contraceptive requirements for this study, please refer to Sectio n 
5.4.5. 
4.2.2. Exclusion Criteria  
The following ex clusion criteria are applicable to all subjects. Subjects presenting with any of the 
following will not be included in the trial.  
Diabetes -specific:  
1. A detec table stimul ated serum C -peptide at any time -point during the screening period, defined 
as >0.2  ng/mL (>0.0667 nmol/L).  
2. Current u se of any oral anti -diabetic medication.  
3. Medical history of islet cell, kidney, and/or pancreas transplant. 
4. Occurrence of six or more sever e hypoglycemic events within six months of enrollment . 
5. Known causes of diabetes other than T1DM.   
6. Diabetic complications such as:  
a. Kidney disease (Stage 3 to 5),  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
39 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  b. Renal dysfunction (macroalbuminuria  defined as protein of 2+ or greater on dipstick, 
MDRD eGFR <60 mL /min/1.73m2) 
c. Proliferative retinopathy (active or untreated)  
d. Diabetic foot ulcers  
e. Amputa tions attributable to diabetes  
f. Severe peripheral neuropathy.  
7. Hemoglobin A1C level of > 10.0%.  
8. Non-compl iance with current anti -diabetic regimen . 
Medical History : 
9. Significant skin conditions involving the area (s) targeted for implantation. Examples include 
but are not limited to recurrent boils/furuncles, extensive surgery or scarring, or lipodystrophy.  
10. Uncontrolled or untreated thyroid disease or adrenal  insufficie ncy.  
11. Active alcohol abuse or history of alcohol abuse within five (5) years of enrollment.  
12. Positive urine drug screen for substances of abuse during the screening period or history of 
drug abuse within five (5) years of enrollment. Medical marijuana use m ay be allowed by [CONTACT_1600] [INVESTIGATOR_804131]/or Sponsor. 
13. Prior history of malignancy with the exception of:  
a. Basal cell carcinoma of the skin;  
b. Squamous cell carcinoma of the skin that has been recurrence free for  
≥five years ; 
c. Appropriately treated in situ carcinoma of the cervix.  
14. Known allergies to portions of the cellular excipi[INVESTIGATOR_804132]-01 manufacturing process ( i.e., bovine, porcine allergies ). 
15. History of severe asthma o r COPD.  
16. BMI ≥ 32 kg/m
2 or <18 kg/m2 at screening.  
17. Active hepatobiliary disease or an AST or ALT >1.[ADDRESS_1109946] at screening or a total bilirubin 
>1.[ADDRESS_1109947] has a history of Gilbert’s disease. 
18. Active infection or known history of Hepatitis B o r C. 
19. Positive serology for HIV at screening. 
20. Evidence of  previous tuberculosis  infection ( including BCG vaccination or positive [COMPANY_003]) . 
21. Negative serostatus for Epstein -Barr virus.  
22. Other abnormal labs at screening : 
a. Platelets <100,000. 
b. Hgb <12 g/dL (males) or  <11 g/dL (females) . 
c. Fasting triglycerides >500  mg/dL. 
d. Estimated Glomerular Filtration Rate (GFR) <60  mL/min/1.73 m2 (using MDRD 
calculator)  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
40 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  e. Clinical lab value outside  normal range, unless deemed as not clinically significant by [CONTACT_35299]. 
23. Sustained hypertension defined as average systolic ≥ 160 mmHg or diastolic ≥ 90 mmHg at 
screening . 
24. 12-lead ECG findings demonstrating: 
a. QTc>450 msec for males or >470 msec for females at screening . 
b. Any other abnormality that is clinically significant or is  deemed as requiring  further clinical 
evaluation by [CONTACT_737]. 
25. Any history of unstable angina  or Class 3 or 4 CHF , or any of the following 
diagnoses/conditions or procedures within the past year: stroke, myocardial infarction, life -
threatening arrhy thmia, major cardiovascular procedure (e.g., angioplasty, planned 
angioplasty, or carotid endarterectomy ), or any other clinically significant cardiovascular 
disease diagnosis or procedure. 
26. History of c oagulopathy.  
27. Any other medical condition, for which in the opi[INVESTIGATOR_689], the subject is not 
suitable for the trial. Examples may include clinically significant medical and non -medical 
conditions, and/or psychiatric disorders. 
Exclusionary Procedures or Medication s  
28. Participation in another stu dy of an investigational drug, device, or graft within five half- lives 
of the experimental agent or [ADDRESS_1109948]  & STUDY INTERVENTIO NS 
5.1. VC-02™ Combination Product Description  
VC-[ADDRESS_1109949] components: (1) PEC -01 pancreatic 
endoderm cells derived from hESC and (2) a durable, removable, Delivery  Device ( DD) designed 
to deliver and retain cells at the local implant site. During the first three (3) to six (6) months following implantation, the VC -02 units are expected to vascularize adequately, and the PEC -01 
cells are expected to differentiate into mature glucose- responsive, insulin -producing cells, capable 
of secreting insulin in response to serum glucose concentration. VC -02 is intended to control blood 
glucose in a more physiologic, sensitive, and homeostatic manner than the various forms of 
injectable insulin and pump therapi[INVESTIGATOR_141339].  
 
 
 
 
 
 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109950] and its two components (PEC -01 and the DD) are 
available in the VC -[ADDRESS_1109951] for the duration 
of the shelf -life.  After implantation, the environmental shipper (s) and temperature logger(s)  shall 
be re turned to ViaCyte  or designee . Additional details will be provided in the study reference 
manual. 
5.1.3. Product Storage, Stability , and Accountability  
The shelf -life of the product  is qualified f   
The “Use By [CONTACT_1782]” is  present on each unit. 
The temperature of the product is maintained in a qualified, temperature -controlled, environmental 
shippi[INVESTIGATOR_804133].,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109952] 
and/or shippi[INVESTIGATOR_804134]. 
The Investigator is responsible for the accountability of all used and unused study supplies.  
Unused or partially used supplies must be returned or destroyed, and accounted for as directe d in 
a study reference manual.  
5.1.4. Dosage and Administration  
All properly consented subjects will receive a unique, study subject ID  number. Those subjects 
meeting eligibility criteria are enrolled at Visit 3/ Day [ADDRESS_1109953] enrolls into:  
• In Cohort 1, subjects are implanted with up to two (2) VC-02-300 units and up to six (6) 
sentinels ; or up to ten (10) sentinels only. 
• In Cohort 2, subjects are implanted with up to  twelve  (12) units.  Of these, no more than  
ten (10) may be the VC-02-300 units , with the remainder being sentinel units.    
During Cohort 2, as alternate device configurations, surgical implant techniques, and/or pharmacological interventions are implemented in order to improve e ngraftment outcomes, a 
subset of patients may be implanted with “control” sentinels. These VC -02-[ADDRESS_1109954] on PEC -01 survivability, engraftment, and 
functionality in a non- perforated delivery device.  
After consultation with the Investigator and/or Surgeon, the Sponsor will determine the overall implantation and explantation strategy for a subject, including the total number of VC-02-[ADDRESS_1109955] will 
be provided by [CONTACT_411150]. 
VC-02-300 units are the dosage formulation intended to provide a measurable, therapeutic benefit 
to enrolled subjects. However,  VC-02- 20 units contain  
.  
 
 
. It is 
anticipated that approximately 200,000 IEQ, equivalent to approximately 20% of normal beta cell 
mass, are required to achieve insulin independence. Assuming the data from Cohort 1 and early 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
43 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  subjects enrolled in Cohort 2 support a dose increase, some subjects in  Cohort 2 may be implanted 
 
Table 2. VC-02 Dosing Projections (75 kg Human) 
Device Type 
and (Quantity) At Implant  
(Cell Input)   
4 Months  (Cell Output)  9 Months  (Cell Output)  
PEC-01 
cells 
(x107) PEC-01 
cells 
(106/kg) Fold 
Safety 
Factor IEQ 
 Per Kilogram 
IEQ IEQ 
 Per Kilogram 
IEQ 
VC-02-20 (6)        
VC-02-20 (10)        
VC-02-20 (12)        
VC-02-300 (1)        
VC-02-300 (10)        
* If more than one VC-02-300 unit is required due to lower levels of achieved clinical efficacy, the delivered 
numbers of tota l PEC- 01 cells and PEC- 01 cells per kg ( cell input) increase commensurately, but the maximum 
target output (IEQ and IEQ / kg) would remain constant  and/or within homeostasis . 
The administration of  the investigational product is performed via implantation on Visit  3 (Day 1).  
The preparation and implantation procedures involve step-by- step instructions which are detailed 
in Section  7.[ADDRESS_1109956] under investigation, “dose” adjustments (e.g., an increase or 
decrease) of the implanted VC -02 are not permitted. However, at the discretion of the Sponsor  and 
after consultation with the Investigator, or if a unit is suspected of malfunctioning or being 
damaged ( Section  13.6 ), explantation  of one VC -02-[ADDRESS_1109957] the VC-02-300 units and all remaining sentinel s explanted.  

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109958]’s source 
documentation.   
5.2. Immunosuppression Medications  
An immunosuppressi ve regimen  will be prescribed for each subject  to facilitate the engraftment 
and long- term function of implanted VC -02 units. The overall regimen may include the f ollowing 
agents  (*Day 1 is Implant Day ): 
• Induction ( Cohort 1)  
o Basiliximab :  Recommended course of  20 mg IV on Day 1  and Day 5. However, it may be 
administered as early as Visit 2 (Week - 4).   
• Induction ( Cohort 2)  
If data collected from Cohort 1 indicate su fficient engraftment and cell viability is achieved 
with basiliximab, its use will continue in Cohort 2. However, if data from Cohort 1 and/or data 
collected in subsequent subjects in Cohort 2 indicate insufficient cell viability is achieved , the 
following  agent may be utilized:  
o Anti-thymocyte globulin (ATG)  recommended course :   
 Day - 2 (0.5 mg/kg IV)  – required dose  
 Day - 1 (1.0 mg/kg IV)  – required dose  
 Day 1  (1.5 mg/kg IV) –  required dose  
 Up to two additional 1.5 mg/kg/day IV doses of ATG may be administe red (on Day 2, 
and/or Day 3). Prior to any additional dose administration of ATG, an absolute 
lymphocyte count (ALC) will be obtained locally. If the ALC has been reduced by [CONTACT_12697] 90% versus the pre -ATG administration level, additional dose(s) of ATG ma y not 
be required. The Investigator should contact [CONTACT_804163].  
However, ATG  may be administered using the above dosing schedule as early as Visit 2 
(Week -4). 
• Maintenance (both Cohorts)  
The starting doses and t arget serum trough concentration levels listed below are 
recommendations. As determined by [CONTACT_804164], 
the doses and target trough levels may be adjusted. 
o Mycophenolate mofetil (MMF): Recommended starting dose of 1 gm PO BID as early as 
Visit 2 (Week -4). Adjust the dose downward for gastrointestinal side effects.    
Mycophenolic aci d (Myfortic) may be taken alternatively to alleviate such side effects.   
Trough level measurements for MMF are not required.  
o Tacrol imus :  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
45 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  - If combined with MMF: Recommended starting dose of 2 mg PO BID as early as Visit 
2 (Week -4); target serum  trough concentration level of 10 -12 ng/mL during the first 
three (3) months. Adjust the dose to maintain a  serum  trough concentration level of  7-9 
ng/mL thereafter.  Serum creatinine values should also be collected in conjunction with 
Tacrolimus trough levels in order to monitor for potential renal toxicity.  
- If combined with sirolimus  and MMF : Recommended starting dose of 0.1 mg/kg per 
day in two (2) equal divided doses to achieve a target serum  concentration of 6- 8 
ng/mL. 
o Sirolimus:  Recommended starting d ose of 0.1 mg/kg/day as early as Visit 2 (Week -4); 
target serum trough concentration level  of 8-10 ng/mL by [CONTACT_804165] - [ADDRESS_1109959]-implant, target serum trough concentration levels of 12 -15 ng/mL for 
the three (3) months after implantation and serum trough  concentration  levels of 10-12 
ng/mL thereafter plus MMF (2 g/day).  
• Anti-inflammatory  (both Cohorts)  
o Etanercept recommended course: 
 Day 1 (50 mg IV*) 
 Day 4, Day 8, and Day 11 (25 mg SC) 
*Subcutaneous administration if required per local labeling. 
o Steroids (e.g., prednisone):  Recommended short -term course of steroids (e.g., 
approximately one-month post- implant) with a controlled taper. The overall dosing and 
taper period will be determined by [CONTACT_804166].  
During the use of steroids, the Investigator should manage fluctuations in blood glucose levels in accordance with local standard of care as needed.  
Additional medications can be prescribed by [CONTACT_804167].  As determined by [CONTACT_737], 
medications and/or doses may be adjusted fo r safety reasons. The Investigator should refer to the 
applicable product labeling and package insert for details on the known and potential risks associated with the use of the immunosuppressive medications prescribed as adjunct treatment for each subject . As needed, the dosages of these medications should be adjusted to achieve the target 
blood concentrations ( Section  7.11.3 ) and to minimize the potential for adverse events.  
As additional data are gathered in this trial, chang es in the required immunosuppressive regimen  
may be necessary to enhance safety and/or efficacy of VC -02.  The Sponsor will notify the sites 
and Ethics Committee (if necessary) of such changes as information becomes available.  
5.3. Other Concomitant Medications  and Treatments  
The S urgeon or Investigator , in consultation with the Sponsor, may prescribe additional 
concomitant medication or treatments  
 
 
  

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109960] -procedure drug regimens (e.g., sedatives, 
anesthetics, and pain relievers) will also be given per standard of care as determined by [CONTACT_804168].  
As additional data are gathered  in this trial, changes in required concomitant medications and/or 
treatments may be necessary to enhance safety and/or efficacy of VC -02. The Sponsor will notify 
the sites and Ethics Committee  (if necessary) of such changes as information becomes availabl e. 
For details related to use of exogenous insulin, refer to Section  5.4.2. 
5.4. Lifestyle Guidelines 
Subjects will be instructed  concerning the Lifestyle Guidelines described below at the times 
indicated in the Schedule of Assessments Table 1. Sites should remind subjects of these restrictions  
several days prior to visits  and reinforce at all visits throughout the trial to avoid adversely 
impacting study procedures . 
5.4.1. Dietary Restrictions  
Subjects must abstain from all food and drink (except water) at least [ADDRESS_1109961] to be fasting can be performed at the originally  scheduled clinic visit. 
Subjects will be counseled on appropri ate dietary and lifestyle g uidelines in accordance with local 
standards of care for T1DM beginning at Day 1 (Visit 3) and expected  to follow the advice 
throughout participation of the trial.  
5.4.2. Exogenous Insulin Treatment and Administration  
Subjects will rema in on exogenous insulin therapy as appropriate to maintain blood glucose control 
throughout the duration of the study. Doses of insulin may be modifie d over the course of the 
study. However, the types and brands of insulin used by [CONTACT_804169]. Also, the insulin delivery method for a subject (e.g., pump or  multiple daily 
injections) should not change without consulting the Sponsor and/or Medical Monitor. Subjects 
are required to log their insul in doses every day  on the study diary throughout participation in the 
trial (Section  7.10.1). 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109962] insulin within three (3) inches of the  sensor.  
5.4.3. Physical Activity  
For a week post -implant, subjects must  limit significant physical activity to ensure optimal healing 
of the incision sites (e.g., activities using large muscle grou ps in the implantation areas).  
During the first four weeks post -implant, subjects should avoid exposure to environments with 
temperature extremes (e.g., saunas, spas, ice baths, etc.)  
Subjects should not perform physically strenuous exercise (e.g., weight training and long- distance 
running) within [ADDRESS_1109963] 30 minutes prior to ECG and vital sign 
determinations.  
5.4.5. Contraception  
All female subjects  and male subjects (who in conjunction with a female partner, as applicable) 
who, in the opi[INVESTIGATOR_163483], are biologically capable of having children and are sexually  
active, must agree to use two acceptable methods of contraception  consistently and correctly while 
VC-[ADDRESS_1109964] appropriate method( s) of contraception from 
the list below. The I nvestigator will instruct the subject on consistent and proper use, and at each 
study visit, will confirm and document consistent and proper  use. In addition, the I nvestigator will 
instruct the subject to conta ct the site  immediately if the birth control method is discontinued or if 
a pregnancy is known or suspected in a male subject’s partner. Acceptable methods of 
contraception include:  
• Use of one of the following double -barrier methods:  diaphragm with spermi cide and a 
condom; cervical cap and a condom; or contraceptive sponge and a condom  
• Use of hormonal contraception (any registered and marketed contraceptive agent that contains 
an estrogen and/or a progestional agent) with one of the following: diaphragm wi th spermicide; 
cervical cap; contraceptive sponge; condom; vasectomy; or intrauterine device ( IUD) . 
• Use of an IUD with one of the following: condom; diaphragm with spermicide; contraceptive sponge; vasectomy; or hormonal contraception (noted above).  
• Vasect omy with one of the following: diaphragm with spermicide; cervical cap; contraceptive 
sponge; condom; IUD; or hormonal contraception (noted above).  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
48 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  [IP_ADDRESS]. Women of  Non-childbearing Potential  
Women of non -childbearing potential will be allowed into the study and w ill not need to follow 
contraception requirements outlined in Section 5.4.5. To be considered of non-childbearing 
potential, women must meet at least one of the following criteria:  
• Reached natural menopause (defined as ≥12 month s of spontaneous ame norrhea in women 
>45 years of age, or ≥six months of spontaneous amenorrhea by [CONTACT_804170] [ FSH] levels in the postmenopausal range as determined 
by [CONTACT_25699]’s reference range), or  
• Had a hysterectom y and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion 
at least six weeks prior to Screening Visit 1 ( Week  -5). 
5.4.6. Other Restrictions  
Subjects should not undergo magnetic resonance imaging (MRI), computed tomography (CT), or 
diathermy treatment while wearing the CGM sensor. The CGM transmitter and sensor should be 
removed because of the magnetic fields and heat used in these procedures . 
As additional data are gathered in this trial, there may be other restrictions imp lemented.  These 
restrictions could be related to the efficacy or safety of VC -02. If required for safety reporting, the 
information will be communicated to sites as quickly as possible in order to inform the subjects and/or Ethics Committee . 
6.  STUDY SCHEDUL E 
The clinic visit schedule  for subjects is  outlined in Table 1 – Schedule of Assessments. With 
documented sponsor permission, on a case -by-case basis, certain protocol -required assessments 
may be performed remotely.  
To minimize v ariability in data, s ites should attempt to schedule visits on the same day of the week 
and same time of day for a  subject throughout the trial. When  multiple procedures occur at a visit, 
the following order  of procedures  should be adhered to as much as possible:  
1. 12-lead ECG  
2. Vital signs ( sitting blood pressure , pulse , and temperature ) 
3. Blood and urine samples  
4. Mixed Meal Tolerance Test  (MMTT) or Simplified Oral Glucose Challenge Test 
(SOGCT) . For visits requiring both an MMTT and an explant procedure, the site may  
perform the MMTT  within five (days) prior to the explant procedure.  
5. Location ultrasounds: May be performed up to three (3) days prior to an explant.  
6. Implant or explant procedures  
7. Other procedures: May be obtained in any order either prior to blood sa mples or after,  but 
not sooner than ECG or vitals.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
49 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Cohort  1 and Cohort  2 subjects follow the same schedule of assessments  (Table 1). A difference 
in the number of sentinels implanted and explanted may occur , but all other schedule d procedures 
remain consistent between Cohort 1 and Cohort 2. 
6.1. Visit  1 / Screening  (Week  -5 to Week  -4) 
It is permissible for this visit to occur over multiple  days. Subjects must be fasted prior to this visit.   
The following procedure s are completed : 
• Obtai n informed consent .  
• Obtain a 12- lead ECG.  
• Obtain vitals. 
• Measure height and weight  
• Collect  demography, medical history ( including smoking status, alcohol frequency, and 
hormonal status, as well as prior (within 30 days) and concomitant medications.  
• Obtai n contact [CONTACT_804171]’s health care provider and family members in 
order to reach subject if other contact [CONTACT_804172]. 
• Perform a complete  physical exam  (PE). 
• Administer the Clarke Survey.  
• Obtain all laboratory  samples per the S chedule of Assessments; disp ense home collection 
supplies for the baseline urine albumin/creatinine sample . 
• Perform urine pregnancy test using the study- provided kit.  
• Conduct the SOGCT . 
• Review eligibility criteria to assess suitability for the trial.  
• Revi ew Lifestyle Guidelines.  
• Contact [CONTACT_804173] -02 for an implant  date.  
6.2. Visit  2 / Screening (Week  -4 to Week  -2) 
Subjects meet ing eligibility criteria will return for Screening Visit 2 ( Week  -4). Subjects must be 
fasted for this  visit. T he following procedures will be completed:  
• Review and confirm continued eligibility criteria . 
• Obtain w eight/vitals . 
• Obtain all laboratory samples  per the Schedule of Assessments.  
Note :  The immune panel blood sample s may be collected at any time b etween Visit [ADDRESS_1109965]’s study qualification is confirmed ( Section  7.11.4).  
• Perform the 4-hour MMTT . This is  the baseline MMTT for efficacy evaluations.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
50 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Dispense Continuous Glucose Monitoring ( CGM ) equipme nt and provide instructions.   
Insert the first sensor at the clinic . Confirm the CGM is functioning prior to the subject 
leaving the clinic.  
• Dispense Self-Monitoring Blood Glucose ( SMBG)  equipment  and provide instructions .  
Use of the meter provided by [CONTACT_804174].  
• Dispense the study diary and provide instructions. This is where the subject will capture 
insulin doses, details on HEs, and SMBG values. Remind the subject that eligib ility for 
the trial requires daily compliance with entr ies between  Visit  2 and 3.  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and c oncomitant  medication s. 
• Contact [CONTACT_804175].  
The expected duration of the Screen ing Period is up to approximately five  weeks.  If the Enrollment 
Visit 3 is scheduled to occur beyond six weeks (>42 days) from  the occurrence of Screening 
Visit 1, sites must  contact [CONTACT_804176]. Depending on the expected duration of 
the delay in conducting Visit 3, an U nscheduled Visit may be required to repeat certain screening 
procedures.  
The overall Screening Period may be accelerated, but a minimum of two weeks must elapse 
between Visit 2 and Visit  3. 
6.3. Visit  3 / Enrollment and Impla ntation (Day 1) 
Subjects must be fasted for this visit. The following procedures will be completed:  
• Ensure e ligibility  criteria continue to be met . 
• Obtain weight/vitals.  
• Perform an abbreviated PE. 
• Obtain all laboratory samples per the Schedule of Assessments.  
• Perform urin e pregnancy test using the study -provided kit. Results must be available before 
the implant procedure commences.  
• Collect and r eview CGM , SMBG, and diary  data and verify subject has demonstrated 
compliance with diary entries ; dispense addition al supplies .  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and Concomitant Medications.  
• Prepare subject  for implantation . 
• Implant VC- 02-300 and sentinel  units. 
• Obtain video and/or photos of the implantation p rocedure ( if requested by [CONTACT_2728] ). 
• Dress the subject with the appropriate compression garments.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
51 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Assess subject for up to four hours post -implantation for AEs. 
• Remind subject to limit significant physical activity to ensure optimal healing at 
implantation  sites.  Instruct the subject on the proper use of all post-implant treatments.  
6.4. Visit  4 (Day 2) 
There is a +1-day window for this visit.  S ubject s do not need to fast for this visit.  T he following 
procedures will be completed:  
• Perform a  targeted  PE focusing on the implantation site (s). 
• Obtain weight/vitals.  
• Collect and review CGM, SMBG, and diary  data; dispense additional supplies.  Provide 
counseling and assistance to subject if there are compliance issues.   
• Dispense immunosuppression drugs and provide inst ructions for dosing (as needed).  
• Assess AEs and concomitant medications . 
Activities noted below to be performed only if an explant is planned for this visit:  
• Perform ultrasound to  locate the unit(s)  planned for expla ntation ( up to 3 days prior ). 
• Explant unit(s).  
• Obtain video and/or photos of the explantation procedure  (if requested by [CONTACT_2728]) . 
6.5. Visit  5 (Week  2) 
There is a ± 2-day window for this visit. Subjects must be fasted for this visit.  The following 
procedures will be completed:  
• Obtain weight/vitals.  
• Perform an abbreviated PE. 
• Obtain laboratory samples per the Schedule of Assessments.  
• Collect and review CGM, SMBG, and diary  data; dispense additional supplies.   Provide 
counseling and assis tance to subject if there are compliance issues.    
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and concomitant medications . 
Activities noted below to be performed only if an explant is planned for this visit : 
• Perform ultrasound to locate the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of the explantation procedure (if requested by [CONTACT_2728]) . 
6.6. Visit  6 (Week  4) 
There is a ±3-day window for this visit. Subjects must be fasted for this visit. At this visit, the 
following proc edures will be completed:  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
52 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Obtain weight/vitals.  
• Perform a n abbreviated PE. 
• Obtain laboratory samples per the Schedule of Assessments.   
• Collect and review CGM, SMBG, and diary  data; dispense additional supplies.  Provide 
counseling and assistance to subject  if there are compliance issues.    
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and concomitant medications . 
Activities noted below to be performed only if an explant is planned for this visit:  
• Perform ultras ound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of the explantation procedure (if requested by [CONTACT_2728]) . 
6.7. Visit  7 (Week  8) 
There is a ± 7-day window for this visit. Subjects must be fasted  for this visit. T he following 
procedures will be completed:  
• Obtain w eight/vitals . 
• Obtain blood samples . 
• Collect and review CGM, SMBG, and diary  data; dispense additional supplies.  Provide 
counseling and assistance to subject if there are compliance issues.   
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and concomitant medications .  
• Perform the safety ultrasound assessment of implantation sites.  
• Conduct the  2-hour MMTT.  
Activities noted below to be performed only if an explant is planned for this visit:  
• Perform ultrasound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of the explantation procedure (if requested by [CONTACT_2728]).  
6.8. Visit  8 (Week  12) 
There is a ± 7-day window for this visit. Subjects must be fasted for this visit. T he following 
procedures will be completed:  
• Obtain weight/vitals.  
• Perform a n abbreviated PE. 
• Obtain all laboratory samples pe r the Schedule of Assessments.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
53 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Collect and review CGM, SMBG, and diary  data; dispense addit ional supplies. Provide 
counseling and assistance to subject if there are compliance issues.  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and concomitant medications . 
• Conduct the 2- hour MMTT. 
Activities noted  below to be performed only if an explant is planned for this visit:  
• Perform ultrasound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of the explantati on procedure (if requested by [CONTACT_2728]) . 
6.9. Visit  9 (Week  16) 
There is a ± 7-day window for this visit . Subjects must be fasted for this visit. The following 
procedures will be completed:  
• Obtain weight/vitals.  
• Perform a n abbreviated  PE. 
• Obtain all laboratory sa mples per the Schedule of Assessments.   
• Administer the Clarke Survey.  
• Collect and review CGM, SMBG, and diary  data; dispense additional supplies.  Provide 
counseling and assistance to subject if there are compliance issues.  
• Dispense immunosuppression drugs  and provide instructions for dosing (as needed).  
• Assess AEs and c oncomitant m edications . 
• Perform the safety ultrasound assessment of implantation sites.  
• Conduct the 2- hour MMTT.  
Activities noted below to be performed only if an explant is planned for this visit: 
• Perform ultrasound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of the explantation procedure (if requested by [CONTACT_2728]) . 
6.10. Visit  10 (Week  20) 
There is a ± 7-day window for this visit . Subjects must be fasted for this visit. T he following 
procedures will be completed:  
• Obtain weight/vitals.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
54 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Obtain all laboratory samples per the Schedule of Assessments. D ispense home collection 
supplies for the urine albumin/creatinine sample.   
• Collect a nd review CGM, SMBG, and diary  data; dispense additional supplies. Provide 
counseling and assistance to subject if there are compliance issues.  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and concomitant med ications.   
• Conduct the 2-hour MMTT .  
Activities noted below to be performed only if an explant is planned for this visit:  
• Perform ultrasound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of  the explantation procedure (if requested by [CONTACT_2728]) . 
6.11. Visit s 11 and 13  (Weeks  26 and 52)  
There is a ± 7-day window for Visit 12. There is a ± 14-day window for Visit 14. Subjects must be 
fasted for these visits. The following procedures will be completed:  
• Obtain 12- lead ECG.  
• Obtain weight/vitals.  
• Perform a  complete PE . 
• Obtain all laboratory samples per the Schedule of Assessments.  
• Perform urine pregnancy test using the study- provided kit (Week 52 only). 
• Administer the Clarke Survey.  
• Collect and review CGM, S MBG, and diary  data; dispense additional supplies.  Provide 
counseling and assistance to subject if there are compliance issues.  
• Perform the safety ultrasound assessment of implantation sites.    
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and c oncomitant m edications . 
• Perform the 4-hour MMTT . 
For all subjects, a ctivities noted below to be  performed only if an explant is planned for this visit:  
• Perform ultrasound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of the explantation procedure (if requested by [CONTACT_2728]) . 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
55 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  6.12. Visit  12 (Week  39) 
There is a ±[ADDRESS_1109966] be fasted for these visits. The following 
procedures will be completed:  
• Obtain weight/vitals.  
• Perform an abbreviated PE . 
• Obtain all laboratory samples p er the Schedule of Assessments.  
• Dispense home collection supplies for the urine albumin/creatinine sample.  
• Administer the Clarke Survey.  
• Collect and review CGM, SMBG, and diary data; dispense additional supplies. Provide 
counseling and assistance to subject i f there are compliance issues.  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and concomitant medications.  
• Conduct  the 2- hour MMTT. 
Activities noted below to be performed only if an explant is planned for this visit:  
• Perform ultrasound to lo cate the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit(s).  
• Obtain video and/or photos of the explantation p rocedure (if requested by [CONTACT_2728]).  
6.13. Visit s 14 and 16  (Weeks  65 and 91)  
There is a ± 14-day window for these visits. Subjects mus t be fasted for this visit. T he following 
procedures will be completed:  
• Obtain weight/vitals.  
• Obtain all laboratory samples per the Schedule of Assessments. D ispense home collection 
supplies for the urine albumin/creatinine sample.  
• Collect and review CGM, SMBG, and diary  data; dispense additional supplies.  Provide 
counseling and assistance to subject if there are compliance issues.  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and c oncomitant m edications . 
• Conduct the 2- hour MMTT. 
Activities noted below to be performed only if an explant is planned for this visit:  
• Perform ultrasound to lo cate the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or photos of  the explantation procedure (if requested by [CONTACT_2728])  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
56 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  6.14. Visit  15 (Week  78) 
There is a ± 14-day window for this visit. Subjects must be fasted for thi s visit. T he following 
procedures will be completed:  
• Obtain weight/vitals.  
• Perform an abbreviated  PE. 
• Obtain all laboratory samples per the Schedule of Assessments.  
• Administer the Clarke Survey.  
• Collect and review CGM, SMBG, and diary  data; dispense additi onal supplies. Provide 
counseling and assistance to subject if there are compliance issues.  
• Perform th e safety ultrasound assessment of implantation sites.  
• Dispense immunosuppression drugs and provide instructions for dosing (as needed).  
• Assess AEs and c oncomitant m edications . 
• Conduct the 4- hour MMTT. 
Activities noted below to be performed only if an expla nt is planned for this visit:  
• Perform ultrasound to locate  the unit(s) planned for explantation (up to 3 days prior).  
• Explant unit (s). 
• Obtain video and/or  photos of the explantation procedure (if requested by [CONTACT_2728])  
6.15. Visit  17 / Study Completion ( Week  104) or Early Termination  
There is a ±[ADDRESS_1109967] will be followed in the long-term, follow -up study  
(VC0 2-201). The following procedures will be completed:  
• Obtain 12- lead ECG.  
• Obtain weight/vitals.  
• Perform a comp lete PE . 
• Obtain all laboratory  samples per the Schedule of Assessments.  
• Perform urine pregnancy test using the study- provided kit . Pregnancy test should occur on 
the same day as the final explantation procedure.  
• Collect all necessary study -related equipmen t. 
• Administer the Clarke Survey.  
• Review CGM, SMBG, and diary  data . 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
57 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Dispense immunosuppression drugs and provide instructions for taper dosing (as 
needed).  
• Assess AEs and c oncomitant m edications . 
• Perform the 4-hour MMTT . 
• Perform the safety ultrasound asses sment of implantation sites.  
• Perform ultrasound to locate  the unit( s) planned for explantation (up to 3 days prior).  
• Prepare subject for explantation procedure : 
− Explant all remaining VC- 02-300 and sentinel units  (if applicable).  
• Obtain video and/or photos of the explantation  procedure (if requested by [CONTACT_2728]) . 
• Review participation requirements  for the long -term, follow -up study (ICD process for 
Protocol VC02- 201 [safety -follow -up study]  follow -up study can be initiated ). 
• Remind subject of the  follow -up Vis it 18. 
6.16. Follow -up Visit  18 (Week  105) 
There is a ± 3-day window for this visit. All subjects , regardless of whether or not they completed 
the trial,  complete this visit to follow -up on unresolved AEs and the post -explantation experience.  
The following proce dures w ill be completed:  
• Obtain weight/vitals . 
• Perform a targeted PE of explantation site(s).  
• Assess AEs and concomitant medications.  
• Obtain photos of the explantation sites (if requested by [CONTACT_2728]) . 
6.17. Unplanned or Unscheduled Visit s 
Unplanned visits may oc cur at any time for reasons of subject  safety  and/or collection of additional 
time-point data . Possible reasons for unplanned visits include but are not limited to:  
• Laboratory testing to evaluate immunosuppression drug levels . 
• Adverse event f ollow -up. 
• Abnormal laboratory test follow -up. 
• Review of b lood sugar values with possible exogenous insulin dose adjustments . 
• Additional p re-operative  evaluations . 
• Post-implant and/ or e xplant site  evaluation (includes evaluation of incision healing) . 
• Suture removal pos t-procedure.  
• Repeat or follow -up ultrasound evaluations (safety or location) . 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
58 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Explant of a VC -02-300 unit or sentinel  unit. 
• Perform a n SOGCT or MMTT.  
• Obtain video and/or photos of an  explantation procedure . 
• Administration of immunosuppression drugs  
Source documentation should reflect the occurrence of all Unplanned Visits. Data may be collected 
from these visits  depending on the procedures  conducted. A subject may need to be in a fasted 
state for Unplanned Vi sits depending on the laboratory tests required. (e.g., lipid panel or  MMTT ).   
7. STUDY ASSESSMENTS  
Every effor t should be made to ensure protocol -required tests and procedures are completed as 
described.  Rarely, circumstances outside the control of the Investigator  may make  it unfeasible to 
perform a cer tain test. In these cases, the Investigator  will take all steps necessary to ensure the 
safety and well -being of the subject. When a protocol -required test cannot be performed, the 
Investigator  will document the reason along with corrective and preventive actions taken to ensure 
normal processes are adhered to as soon as possible.   
In addition to the protocol -required assessments, the Investigator may conduct additional tests or 
procedures to e nsure the safety and well -being of a subject in accordance with  local standards of 
care.  Source documentation should reflect the occurrence of these additional procedures. 
7.1. Clinical Evaluations 
7.1.1. Physical Examination  
There are three types of PEs performed over the course of the study: complete, abbreviated, and 
targeted . All PEs must be performed by [CONTACT_26359]. It is preferred that 
the same person conduct the same -type of PE for each subject over the course of the study Other 
body systems should be evaluated as per the judgment of the Investiga tor as needed to evaluate 
AEs.  
Details of each are described below.  
• A complete  PE is  performed at screening  Visit  1 (Week  -5), Visit 11 ( Week  26), Visit 13 
(Week  52) and Visit 17 ( Completion /  Early Termination ). Body systems e valuated are:  
general appear ance, skin, head/eyes/ears/nose/throat, heart, lungs, abdomen, extremities, 
neurological, back/spi[INVESTIGATOR_1304]/flank area, and lymph nodes. Results must be recorded in 
source documents and any significant findings on the screening PE must be recorded  on 
the Medical  History CRF. All  abnormal, c linically significant changes from the screening 
PE must be captured as AEs.  
• An abbreviated PE is  performed at Visit 3 ( Day 1), Visit 5 (Week  2), Visit  6 (Week  4), 
Visit 8 ( Week  12), Visit 12 (Week  39) and Visit  15 (Week  78). T he abbreviated exam 
assesses the heart, lungs, abdomen, extremities, and skin ( including implantation  and/or 
explantation  site[s]). 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
59 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • A targeted PE focus es on the evaluation of the healing status at the implantation and/or 
explantation sites.  Targeted PEs  are performed at Visit 4 ( Day 2) and Visit 18 
(Week  105) in addition to any visit  following a sentinel explant  (e.g., Visit  10, Visit 13), 
inclusive of an unplanned visit if it is related to the post- surgical evaluation.   
7.1.2. Body Weight  
Subjects are weighed at  every visit on the site’s designated, calibrated scale throughout the study.  
Preferably, w eight is taken at approximately the same time of day, after voiding, and while wearing 
a gown or light clothing (no shoes or socks). W eight is  reported in eithe r pounds or kilograms . 
7.1.3. 12-lead ECG  
A single, supi[INVESTIGATOR_050] 12- lead ECG is  obtained on the site’s equipment at the visits  noted in the Schedule 
of Assessments. ECGs should be performed after the subject has rested for at least 10 min utes in 
a supi[INVESTIGATOR_804135]. The screening ECG is the baseline  
ECG for the study. All ECGs collected during the trial (planned and unplanned) should be 
reviewed at the site for safety monitoring. The Investigator is responsible for retaining copie s of 
the ECG reports.  
All abnormal, significant findings on the screening ECG must be recorded on the Medical History 
CRF. Over the course of the study, any abnormal, clinically significant changes from the screening 
ECG must be captured as AEs.  
7.1.4. Vitals:  S itting Blood Pressure, Pulse R ate, and Temperature 
Vital sign measurements include a single measurement of sitting blood pressure  (BP) , pulse rate, 
and temperature . BP and pulse rate should be measured using  the site’s eq uipment . The following 
method shoul d be used to record sitting BP  and pulse rate for subjects.  
• Subjects will refrain from nicotine  products and/or caffeine at least 30 minutes prior to 
measurements.  
• Subjects should be seated in a chair with their backs supported, feet flat on the floor , and 
arms bared and supported at heart level.  
• The appropriate cuff size must be used to ensure accu rate measurement and used 
consistently throughout the study.  
• Readings  should be done  on the same arm at each visit,  preferably the non -dominant arm.  
• Measurement should begin after at least five minutes of res t. 
• Assessment of pulse r ate can be manual or aut omated. W hen done manually, the rate 
should be counted in the brachial/radial artery for at least [ADDRESS_1109968] (MMTT)  
MMTTs are conducted after all other vital signs evaluations and laboratory tests have been collected. The MMTT test should only be started if the subject has been fasting for at leas t eight 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
60 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  (8) hours. All MMTT supplies will be provided by [CONTACT_16015]. Basal exogenous 
insulin will be continued during the test, but any short -acting insulin will be withheld starting four 
hours prior to starting the test.  Prior to initiating the MMTT, the subject’s fasting glucose will be 
tested at the site and the value must be within  70-200 mg /dL to begin the MMTT. If the fasting 
glucose is not initially within range, the site may recheck levels while the subject is still at the 
clinic. If the fasting glucose remains outside of the allowed range, the subject must return to the 
site within the visi t window and attempt the MMTT again.  
An intravenous catheter can be placed in a patent vein in the subject’s arm for the collection of 
blood samples . Insertion of the catheter should occur at least [ADDRESS_1109969]. At time = 0, the subject drinks Boost® Hi -Protein 
(volume equal to 6 mL/kg body weight to a maximum of 360 mL ). The entire drink must be 
ingested within [ADDRESS_1109970]  
The 4-hour MMTT  is conducted  during Visit  2 (Week  -4), Visit 1 1 (Week  26), Visit  13 
(Week  52), Visit 1 5 (Week 78), and Visit 17 (Completion or ET ). In addition to the time = [ADDRESS_1109971]® meal test . 
7.2.2. 2-Hour Mixed Meal Tolerance Test  
The 2 -hour MMTT is conducted during Visit 7 (Week 8), Visit 8 (Week 12), Visit  9 (Week  16), 
Visit 10 (Week 20), Visit 12 (Week  39), and Visit 14 (Week  65), and Visit 16 (Week 91) .  In 
addition to the time = [ADDRESS_1109972]® meal test.  
7.3. Simplified O ral Glucose Challenge Test (SOGCT) 
All subjects complete the SOGCT at Visit 1 to confirm  a stimulated C -peptide level >0.2 ng/mL 
is not presented (per the exclusion eligibility criterion). A fter all other required fasting blood and 
urine samples for the vi sit have been collected, a fasting C -peptide sample is collected and at time 
= [ADDRESS_1109973]® Hi -Protein (volume equal to 6 mL /kg body weight to a 
maximum of 360 mL ). The entire drink  must be ingested  within [ADDRESS_1109974] .  
7.4. Implantation Procedure 
Implantation occurs at Visit 3 ( Day 1). The number of  VC-02-[ADDRESS_1109975] has been enrolled in Cohort  1 or Cohort  2 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
61 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  (Sections 3.1  and 3.2). All units are implanted   
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
   
A detailed description of the implantation procedure and surgical technique will be provided in the 
VC-[ADDRESS_1109976] appropriate implantation procedure to be 
followed (e.g., placement  of implanted units, number of incisions, dissection technique). As this 
is a FIH study, there is the possibility the implantation procedures will be modified based on data collected . To support the safety, tolerability, and efficacy profile of VC -02, updates and additional 
training on the surgical procedur es may  occur as needed during the study. 
7.4.1. Post-Implant Discharge Instructions and Assessm ents 
Immediately following the implant procedure, the subject will remain in the clinic for up to four hours following the procedure to monitor for AEs. Clinical monitoring will be performed to 
identify and assess: bleeding, bruising, redness, localized swelling, pain (discomfort), and any 
other cl inical significant conditions.  
Additionally, subjects will be monitored for potential immunological reactions to the implantation 
by [CONTACT_804177]:  anaphylaxis, acute breathing problems , angioedema, 
severe implantation site reactions at more than one site, diffuse and severe erythematous rash, diffuse and severe urticarial , new onset mu lti-joint arthralgia , or swelling. Occurrence of any of 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109977] is at the discretion of the Surgeon 
and/or Investigator. Upon discharge, t he subject should be provided instructions regarding the 
required Lifestyle Guidelines ( Section  5.4), proper wound care and evaluation, and any prescribed 
concomitant  therap ies and/or treatments required to facilitate the impla ntation  healing and 
engraftment process ( Sections  5.2 and 5.3). For the week following the implantation, subjects are 
advised to limit significant physical activity to ensure optimal healing.  
Any additional pre - or post -operative evaluations or visits conducted beyond the protocol -specified 
study visits are at the discretion of the surgeon and/or Investigator and should be c aptured as an 
Unplanned Visit.  
7.5. Photographs of Implantation and E xplantation Sites 
Photographic images of subjects may be obtained during the study to visually document the 
anatomical implantation and explantation sites.  The Sponsor will notify the Investigator when 
photographs are requested and provide i nstructions for capturing the appropriate images. To 
maintain subject confidentiality, images will be limited to the implantation and explantation sites 
and will not include images of the subject’s facial features  or any other uniquely identifiable 
physical features . If such features  are unintentionally captured, the images  will be de -identified .  
The Sponsor  will upload images to a secure, limited -access repository,  and these images may be 
used to refine the surgical procedure s, provide site training, or for other educational purpose s 
related to the clinical development of VC -02. 
7.6. Vide o of Implantation and Explantation Procedures  
Video footage involving subjects may be obtained during the study to visually document and 
evaluate the implantation and explantation procedures. The Sponsor will notify the Investigator 
when video is requested and provide instructions for capturing the appropriate images. To maintain 
subject confidentiality, footage  will be limited to the implantation and explantation sites during 
the procedure and will de -identify any  images involving the  subject’s facial feat ures or any other 
uniquely identifiable physical features. The Sponsor will upload images to a secure, limited -access 
repository and these images may be used to refine the surgical procedures, provide sit e training, 
or for other educational purposes relate d to the clinical development of VC -02.  
7.7. Ultrasound Monitoring  
Ultrasound monitoring will be performed by [CONTACT_804178].  The central 
imaging vendor will perform validation of the machine utilized to capture images at each site. For 
consistency of results, it is recommended the same technician  at the site perform all ultrasound 
evaluations on a subject and that the same machine be used on a subject throughout the trial.  
Ultrasound monitoring in this  study serve s two purposes:  
1. Safety evaluations t o monitor graft performance ; and 
2. To pre -identify the anatomical location of implanted units prior to a n explantation procedure.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
63 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  These purposes are discussed in more detail below.  
• Safety Ult rasounds :  
 
 
 
 
 
 
  
 
 
 
The safety ultrasound images will be captured, transmitted, and analyzed by [CONTACT_804179]. Safety ul trasound ima ges are required at Visit  7 (Week  8), Visit 9 
(Week  16), Visit 11 ( Week  26), Visit 13 ( Week  52), Visit  15 ( Week  78), and Visit  17 
(Week  104). The central imaging vendor’s reports should be evaluated by [CONTACT_804180]. The 
Investigator may order  follow -up or repeat tests for additional evaluation of potentially 
significant results. The Sponsor should be contact[CONTACT_804181] . 
• Location Ultrasounds : These u ltrasou nd evaluations will be performed within three (3) 
days prior to a ll scheduled sentinel and/or VC -02-300 unit explantation for surgical 
planning purposes. The technician locates the unit(s) planned  for explant and then outlines 
its location with surg ical marker.  This allows  the Surgeon to minimize tissue trauma and 
reduces the likelihood of disturbing adjacent implants .  
 
 
 
If a safety  ultrasound procedure and anatomical location  ultrasound are required at the same visit , 
both can be completed within the same imaging ses sion. Conversely, there may be visits where 
safety  ultrasounds are required but do not correspond to a visit requiring an explant procedure, and 
therefore, location ultrasounds (surgical marking) are not required (and vice versa). Refer to the 
Schedule of Assessments for the complete listing of when any ultrasound imaging may be required. 
Other clinical studies conducted by [CONTACT_804182]  a similar product indicate the established 
ultrasound imaging procedure i s successful at imaging implanted units and is appropriate for the 
purposes identified above. If modifications to the ultrasound procedure are considered necessary 
based on data collected over the course of the trial, sites will be notified. Further information will 
be available in the central imaging core lab manual.  
7.8. Explantation of VC -02™ Combination Product  
 
 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109978] the site if any problems occur.  
As this is a FIH study, there is the possibility the explantation procedure and technique  will be 
modified based on the data collected. The Sponsor will communicate with the site  Surgeons to 
understand where improvements may be made. Updates will be communicated to other sites as 
appropriate , with  additional training provided if  required. 
7.8.1. Explantation of VC -02-20™ Sentinel  Units  
All sentinel units will be explanted at time -points to be determined by [CONTACT_1034] (refer to the 
Schedule of Assessments). In both Cohort 1, up to ten (10) VC-02- 20 sentinels  and in Cohort 2, 
up to twelve  (12) VC-02- [ADDRESS_1109979]. The number of sentinels 
implanted will be determined by [CONTACT_804183].  
The decision will be based on the available data from previous subjects as well as on the 
availability of anatomical space for surgical implantation.  
7.8.2. Explantation of VC -02-300™ Units  
As outlined in the Schedule of Assessments, VC-02-[ADDRESS_1109980] to 
officially withdraw from the study  (Section  13.6 ). Although the sentinel units implanted in subjects 
are expected  to behave similarly to the VC -02-[ADDRESS_1109981]  
All explanted VC-02-20 sentinels and VC-02-300 units will be placed immediately in a fixative 
solution and shipped to the Sponsor for histologic assessment . Explant preparation and s hippi[INVESTIGATOR_804136].  Systematic , histologic evaluation of sentinel explants 
will help inform the Sponsor as to the expected performance of the larger VC -02-300 units while 
the study is ongoing. Histological assessment of the units will be performed by [CONTACT_804184]:  
  

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
65 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared    
 
 .
 
Data from this evaluation may be captured in a separate database and described in a separate study 
report. The data may be used to optimize the surgical  procedure s and technique , the anatomical 
locati on of implants, or the perioperative care associated with VC -02. Results from these 
assessments may be compared to the Sponsor’s database  
7.10. Blood Glucose Monitoring  
Throughout the trial, the exogenous insulin requirements  of enrolled subjects are managed and 
titrated by [CONTACT_737] (or qualified designee) as needed to maintain glycemic control  in 
conjunction w ith standards of care .  For purposes of this study, the diary entries made by [CONTACT_12912] (e.g., insulin doses, SMBG values, and HE occurrences) are the main  sources of 
information available to the Investigator  to assist with treatment decisions. CGM data  may be 
utilized for treatment decisions in accordance with local labeling market approvals.   
In addition to Investigator review of glucose trends, insulin dosing, and HE occurrences, the 
Sponsor will conduct routine reviews of blood glucose data. These data are collected as part of the required study procedures.  Subjects record insulin dosing and all HE occurrences on 
a study diary and glucometer data are electronically downloaded. The data are then 
available in near real -time for review. If potentially concerning trends are e videnced for an 
individual subject, the Sponsor will notify the Investigator and request for follow -up with 
the subject  to occur if necessary.  
Blood glucose monitoring is  performed through various methods during the study to ensure proper 
glucose control :  
• Laboratory test s (Sections  7.2, 7.3, and 7.11) 
• Continuous Glucose Monitoring (Section  7.10.2 ) 
• Self-Monitoring Blood Glucose ( Section  7.10.3 ) 
Data from these methods will  be available to the Investigator via reports from laborator ies, study 
diaries, and downloads or entries  from CGM and SMBG meters to facilitate treatment decision s.  
The glucose monitoring data collected between Visit 2 ( Week  -4) and Visit  3 (Day 1) establishes 
the baseline profile of each subject’s glycemic control (e.g. , the percent time spent at various blood 
glucose cutpoints  per CGM data, SMBG blood glucose levels, exogenous insulin doses, and 
frequency of HEs). 
During the study, decreasing requirements for exogenous insulin may be achieved gradually as 
cells differentiate into mature, insulin -secreting cells. This reduction in exogenous insulin dose 
typi[INVESTIGATOR_804137] a period of three (3) to six (6) months post- implantation , but 
may occur later in some patients . In addition to the requirement for frequent review of the available 
sources of subject -reported data, Investigators are encouraged to engage in r outine contact [CONTACT_108806] (e.g., phone calls, texts, and emails) and/or schedule Unplanned Visits between the 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
66 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  protocol -required visits to facilitate insulin adjustments and to address any potential safety issues 
as needed . 
A study reference manual may f urther outline the various logs and data collection portals available 
to the Investigator.  
7.10.1. Study Diary  
Starting at Visit 2 ( Week  -4) and throughout the duration of participation in the trial , subject s are 
required to enter or download all SMBG values, HE o ccurrences  and associated symptoms , and 
insulin dos es into the study diary on a daily basis . Because treatment decisions are based , in part, 
on the availability of this information, the Investigator must make  all reasonable efforts to ensure 
subjects compl y with the requirement for daily entry of this important information.  After 
implantation, if a subject demonstrates  repeated non- compliance  with this requirement, the 
Investigator must document efforts to cor rect and prevent future non -compliance in the su bject 
source records.  
At a minimum, diary data must be reviewed by [CONTACT_804185]. Review of available study diary data at each visit mu st be 
documented in the subject source records. Subject diary entries may  also be available for review 
in near real -time by [CONTACT_804186], and a utomated e -mail alerts 
may be configured for alert to the Investigator for occurrences of potential safety -related issues 
(e.g., if a SHE is reported or if the frequency of HEs reported within a certain period requires 
further evaluation).   
7.10.2. Continuous Glucose Monitoring (CGM) 
All subjects will be provided with a CGM  system . Previous experience with CGM is not a 
requirement of stud y entry, but all subjects are required to use the Sponsor -provided CGM during 
study participation. Based on the labeled indication of the CGM in use, diabetes treatment 
decisions may  be based on CGM data collected. S ubjects relying on CGM data for treatmen t 
decisions will be required to  be compliant with CGM usage and wear the CGM for the entire two -
year study and also periodically sync the data , so that near -real time access may be available to the 
Investigator and Sponsor . A study reference manual will fu rther outline the logistics  with respect 
to CGM use and data collection .  
All CGM supplies and instruction manuals  will be provided by [CONTACT_1034] . Site personnel will  
instruct the subjec t on proper use and care  at Visit 2 ( Week  -4) and as needed throughout the study .  
This training includes assisting the subject with the insertion of the first sensor needle prior to 
leaving the clinic  at Visit  2. The CGM system  is conf igured to alert the subject in the event blood 
glucose values approach hypoglycemi c level s. 
The CGM data collected for this trial will be used to evaluate secondary and exploratory endpoints.  Data from the two weeks prior to appropriate clinic visits will be used in order to calculate the 
CGM endpoints ( e.g., percent of time a subject’s  blood sugar is  <54 mg/dL, ≥54 to <70 mg/dL, 
≥70 mg/dL to ≤180 mg/dL, and > 180 mg/dL ).  Other endpoints using CGM data may be evaluated 
and, if so, will be described in the Statistical Analysis Plan (SAP).  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
67 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  7.10.3. Self-monitoring Blood Glucose (SMBG)  
SMBG supplies including a Sponsor -provided portable meter,  test strips , lancets, control solution, 
and sharps containers will be provided and required for use  by [CONTACT_804187] 2 
(Week  -4). Instructions for routine SMBG monitoring via fingerstick and calibration of the  meter 
will be provided to each subject. The r ecommended frequency of  SMBG monitoring will be 
determined for each subject by [CONTACT_737].  All SMBG values , whether conducted for routine 
blood glucose monitoring, confirmation of hyperglycemia or hypoglycemia, or due to the 
calibration requirements of the CGM equipment, will be logged on a study diary.  
7.10.4. Definition, Classification , and Management  of Hypoglycemic Events  (HEs)  
All SMBG or CGM values of < 54 mg /dL must be captured by [CONTACT_804188] a HE.  
Additionally, i f a subject does not have a blood glucose value  available, but has symptoms of a 
HE, the HE must still be captured in the diary  as an HE. For any SHE experienced between 
scheduled clinic visits, the subject must enter the data on the diary and also contact [CONTACT_804189].  
At Visit 3 ( Day 1) and each clinic visit  thereafter, the Investigator will review the subject’s HE 
entries on the study diary, CGM and SMBG values , and any other supportive information. Each 
HE occurring beyond Visit  2 (Week  -4) must be captured on a CRF  and will b e classified based 
on the definitions below . Per standards of care, t he Investigator should also evaluate any HE s 
occurring between Visit  [ADDRESS_1109982] , but they are not captured on the 
CRF . 
• Severe hypoglycemi c event (SHE) :  an event requiring assistance of another person to 
actively administer carbohydrate, glucagon, or other resuscitative actions. 
• Documented symptomatic hypoglycemia :  an event accompan ied by [CONTACT_11017][INVESTIGATOR_804138] <70 mg /dL (3.9 mmol/L).  
• Asymptomatic hypoglycemia : an event with measured plasma glucose of <54 mg /dL 
(3.0 mmol/L) in the absence of symptoms.  
• Probable symptomatic hypoglyce mia: subject  reports typi[INVESTIGATOR_804139]  a temporally -associated SMBG  or CGM value.  
• Pseudo- hypoglycemia  or relative hypoglycemia : an event is reported by [CONTACT_1130] , but the 
associated SMBG or CGM value  is ≥70 mg /dL (3.9 mmol/L) . 
The frequency of HEs will be captured and counted over the course of the study. In addition, the 
Sponsor will consider defining additional HEs using the CGM data on an exploratory basis. The Investigator may request an Unplanned Visit to review study dia ry entries and determine if 
modifications in insulin dosing a re necessary to reduce the occurrence of HEs. Based on available 
information, the Investigator should make appropriate decisions regarding the insulin therapy to mitigate HE occurrences.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109983] the majority of  protocol -required, biological 
samples collected from subjects in the study . Details regarding the laboratory specimen 
preparation, handling, storage, shippi[INVESTIGATOR_804140]  a separate 
laboratory reference manual. All protocol -required samples will be collected at the time- points 
indicated on the Schedule of Assessments.  
As needed (e.g., immunosuppression drug levels, absolute lymphocyte cou nts [to confirm adequate 
pre-implan t immunosuppression has been achieved], or urgent medical events), local laboratories 
available to a site may be utilized.  
All laboratory test results outside of normal range should be evaluated by [CONTACT_804190]. The Investigator may 
order repeat tests once for additional evaluation of potentially significant results. The Sponsor 
should be contact[CONTACT_804191].  
7.11.1. Routine Clinical Laboratory Evaluations  
Subjects will have  routine laboratory assessments performed throughout the study, including:  
• Hematology : hemoglobin, hematocrit, RBC count, platelet count, WBC count, total 
neutrophil s, eosinophils, monocytes, basophils, and lymphocytes . 
• Chemistry : BUN, serum creatinine, total calciu m, sodium, potassium, chloride, 
bicarbonate, magnesium, phosphate, uric acid, ALT, AST, LDH, alkaline phosphatase, 
total bilirubin (direct and indirect bil irubin reflexively measured only when total bilirubin 
is greater than the ULN), creatine phosphokinase, albumin, and total protein.  
If a subject demonstrates an ALT and/or AST val ues of >[ADDRESS_1109984] every five to seven days until the values return to <[ADDRESS_1109985] value of >[ADDRESS_1109986] with total bilirubin ≥[ADDRESS_1109987] and alkaline phosphatase <[ADDRESS_1109988] will require re -testing every three  to five days. 
• Fasting serum lipid panel : total cholesterol, HDL -C, calculated LDL -C (Friedwald), 
triglycerides, VLDL.  Non -HDL -C will be calculated as TC – HDL -C. When triglycerides 
are >400  mg/dL, another sample will need to be collected from the subject and a directly 
measured LDL will be done.  
• Urinalysis (central lab dipstick) : pH, protein, blood, ketones, leukocyte estera se, and 
nitrites.  M icroscopy is done if the dipstick sample is positive for blood, nitrites, leukocytes, 
and/or protein. A bacterial culture and sensitivity will be  done if nitrites or leukocyte 
esterase are positive. Another sample will need to be collec ted from the subject and 
submitted in order to perform the cu lture and sensitivity testing.  
At visits where a urine albumin/creatinine ratio is performed , the determination must be 
made on the first morning void.  
• Serology:  screening for HB  core and sAg /Ab, HCV, HIV (1&2) , CMV IgG, and EBV  IgG.  
Subjects are also tested post -implant via  CMV PCR at Weeks 12 and 26. Additional CMV 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
69 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  IgG and IgM testing is completed at Week 52 and Week 104 only if previous CMV testing 
was negative . 
• Other : HbA1C, ultrasensitive C -peptide (collected in conjunction with MMTTs pre -
stimulation (time = 0) and post -stimulation at a 90 minute [+/ - 10 minutes] timepoint) , 
urine pregnancy tests , Quantiferon, renal  function evaluation via MDRD  eGFR  calculation, 
and TSH (screening).  
7.11.2. Pregnancy  Tests  
A urine pregnancy test  is administered to all women at Visit 1 ( Week  -5), at Visit 3 (pre -implant), 
and post -implant at Visit 13 (Week 52) and Visit 17 (Week 104) or early termination. However, 
additional p regnancy tests may be completed if the Investigator suspects a possible pregnancy, as 
per request of the Ethics Committee , or if required by [CONTACT_427]. 
7.11.3. Immunosuppression Drug Levels and Safety Labs  
Certain drugs prescribed as part of each subject’s immunosuppressive regimen may require 
additional blood testing to ensure appropriate concentrations are achieved to facilitate the 
engraftment and long- term function of implanted VC -02 units. R outine testing of concentration 
levels is required to avoid drug toxicity and any associated adverse even ts. Refer to Section 5.2 for 
details on the planned immunosuppression regimen. 
Based on the immunosuppression regimen prescribed for the patient, and after discussions between 
the Sponsor and Investigator, the target concentration of each applicable drug, as well as the 
frequency of any additional blood testing required to obtain concentration results  and assess safety 
(e.g., additional hematology and chemistry testing) , will be included as part of the implantation 
strategy plan for the subject. Blood collections required to measure immunosuppression drug 
levels may be collected at  regularly scheduled protocol visits or at an Unplanned Visit as needed, 
depending on the frequency of the required drug concentration monitoring.  
7.11.4. Immune  Panel  
Blood samples for hu moral and cellular immunity testing  will be obtained at specific time -points 
throughout the trial  as listed in the Schedule of Assessments . The panel of immune function tests 
includes those listed below: 
•  
  
  
  
  
  
  
Blood samples will be sent to a central or third -party lab with results sent to ViaCyte for possible 
inclusion in the clinical study database. The results of th ese tests will help inform ViaCyte’s 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109989] qualifies for the study. A dditional details a re 
provided in a separate laboratory manual.   
7.11.5. Reserve Blood Samples  
Additional blood samples fr om subjects may be collected starting at Visit  2 and at up to four (4) 
additional study visits for investigational assessment of biomarkers that  could be associ ated with 
the cellular viability and durability of the implanted VC -[ADDRESS_1109990]. The number of biomarkers 
assessed will be limited by [CONTACT_804192], but will not include any genetic testing.   
If the additional blood samples are collected, a s much as 5 mL of blood could be collected at each 
time point.  Results of these tests may not be reported to the site during the course of the study.  
Additional details may  be provided in a separate laboratory manual.  
7.11.6. Blood Volumes 
Total blood collection volumes from scheduled visits requiring lab assessments are not planned to 
be greater than 700 mL  over the course of the trial. O f the 18 clinic visits, there are five (5) visits 
where blood volumes are estimated to be up to approximately 80 mL: Visit  2 (Week  -4), Visit 11 
(Week  26), and Visit  13 (Week  52), and Visit 17 ( Week  104). At other visits, the blood volume 
required ranges from 0  mL to 60 mL . 
If all allowed reserve blood samples ( Section  7.11.5) are coll ected, this would result in up to an 
additional 25  mL of blood collected during the trial.  
Additionally, it is expected that up to approximately 15 mL  of blood may be collected each time 
the site tests the immunosuppression drug concentrations and the associated safety tests.  
For all subjects, blood collections are not planned to occur more frequently than once per week unless there is a need for an Unplanned V isit. 
7.12. Clarke Survey  
The Clarke Hypoglycemia Unawareness Survey  (Appendix 1) is a validated scoring system used 
to measure the degree of awareness a subject with T1DM has to symptoms associated with 
hypoglycemia (Gold, Macleod, & Frier, 1994) . It will be administered at Screening Visit 1 to 
determin e if the inclusion criterion (score ≥  4) is met. Subjects will then complete the Clarke 
Survey at the following additional time points: Visit 9 (Week  16), Visit  11 ( Week  26), Visit 12 
(Week  39), Visit 13 ( Week  52), Visit 15 ( Week  78), and Visit 17 ( Week  104).   
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1109991] will be 
questioned about AEs and pregnancies (if applicable) at each clinic visit. 
8.1. Adverse Events 
An adverse event ( AE) is any untoward medi cal occurrence in a clinical investigation subject 
administered a product or medical device . Adverse events need not necessarily have a causal 
relationship with the tre atment or usage.  
Examples of AEs include, but are not limited to:  
• Abnormal test findings;  
• Clinically significant symptoms and signs  (changes from baseline status) ; 
• Clinically significant changes in physical examination findings;  
• Hypersensitivity; 
• Sensitization to the ; 
• Progression/worsening of underlying disease  (includes worsening diabetes , as assessed by 
[CONTACT_737]) 
All observed or volunteered AEs regardless  of suspected causal relationship to the investiga tional 
product will be repo rted as described in the following sections.  
For all AEs, the Investigator must pursue and obtain information adequate both to determine the 
outcome of the AE and to assess whether it meets the criteria for classification as a serious adverse 
event ( SAE ) requiring immediate notification to the Sponsor  and the Ethics Committee . For all 
AEs, sufficient information should be obtained by [CONTACT_804193]. The Investigator is required to assess causality.  Follow -up by [CONTACT_522204] a level acceptable to the Investigator, 
and the Sponsor concurs with that assessment.  
As part of ongoing safety reviews conducted by [CONTACT_1034], any non-serious AE that i s 
determined by [CONTACT_804194] a SAE. To assist in the determination of case seriousness, further information may be requested from the Investigator to 
provide clarity and understanding of the event in the cont ext of the clinical trial.  
As required on the AE  CRFs, the Investigator will use the National Cancer Institute Common 
Terminology Criteria for Adverse Event (NCI -CTCAE) guidelines to describe the maximum 
intensity of the AE. For purposes of consistency, these intensity grades are defined as follows:  

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
72 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  MILD  Asymptomatic, or mild symptoms, clinical or diagnostic observations noted; 
intervention not indicated . 
MODERATE  Local or noninvasive intervention indicated . 
SEVERE  Medically significant but not immediately life threatening, hospi[INVESTIGATOR_255130].  
LIFE -THREATENING Life-threatening consequences, urgent intervention indicated . 
DEATH  Death related to AE . 
Note the distinction between the severity and the seriousness of an AE.  A severe ev ent is not 
necessarily an SAE. For example, a headache may be severe ( medically significant ) but would not 
be classified as serious unless it met one of the criteria for SAEs (See Section  8.2).  
In addition, if the Investigator determines an SAE is associated with study procedures, the 
Investigator  must record this causal relationship in the source documents  and CRF, as appr opriate, 
and report such an assessment in accordance with the SAE reporting requirements, if applicable.  
It should be noted that the form for collection of SAE information may not be the  same as the AE 
CRF.  Where the same data are collected, the forms must be completed in a consistent manner. 
AEs should be reported us ing concise medical terminology.  
8.1.1. Causalit y Assessment of Adverse Events  
The Investigator’s assessment of causality must be  provided for all AEs (serious and non- serious).  
In relation to implantation w ith VC -02, there are three (3) main components to assessing causality.  
The Inve stigator’s causality assessment must include a determination of whether there exists a 
reasonable possibility that:  
• The investigational product (VC- 02) itself caused or contributed to t he AE. 
• The surgical procedure (implantation or explanation) caused or contributed to the AE.  
• The immunosuppression drug regimen caused or contributed to the AE. 
In eval uating the causal relationship of an AE to VC -02, the surgical procedures, and the 
immunosuppression regimen , it is possible for the Investigator to determine causality as being 
associated to one or more of these factors. Conversely, the Investigator can determine that none of these relate to the AE.  
If the Investigator’s final determination of causality is unknown , and the Investigator does not 
know if the investigational product , surgical procedure , or immunosuppression drugs  caused the 
event, then the event will be classified  as “related to investigational product” for reporting 
purposes. If the Investigator’s causality assessment is “unknown but not related to investigationa l 
product”, this should be clearly documented on study records.  
Relationship of an AE to VC- 02, the surgical procedure s, and the immunosuppression drugs  will 
be assessed as follows:  
Not Related (Unrelated or U nlikely Related ): A clinical event including l aboratory test 
abnormalities with out a temporal rela tionship to the investigational product exposure , the surgical 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
73 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  procedures , or the immunosuppression drugs, which makes a causal relationship improbable, 
and/or in which other drugs, chemicals, or underlyi ng disease provides plausible explanations.  
Possibly R elated:  A clinical event, including laboratory test abnormality, with a reasonable time 
sequence to exposure of the investigational product , the surgical procedures, or the 
immunosuppression drugs, but  which could also be explained  by [CONTACT_19010].  
Definitely Related: A clinical event, including laboratory test, occurring in a plausible time 
relationship to the investigational product exposure , surgical procedures, or the 
immunosuppression drugs, a nd which cannot be explained by [CONTACT_113395].  
8.1.2. Expected Adverse Events 
Refer to Section  1.4.1.  
8.1.3. Determination of  Abn ormal Laboratory Test Values or A bnormal Clinical 
Findings  as Adverse Event  
The criteria for determining whether an abnormal, objective test finding should be reported as an 
AE are as follows:  
• Test result is associated with accompanying symptoms, and/or  
• Test result is not associated with  a known, pre -existing condition or part of the subject’s 
medical history, and/or  
• Test result requires additional diagnostic testing or medical/surgical interve ntion, and/or  
• Test result leads to discontinuation from the study, significant additional concom itant drug 
treatment, or other therapy, and/or  
• Test result is considered to be an AE by [CONTACT_394548].  
Merely repeating an abnormal test, in the a bsence of any of the above conditions, does not 
constitute an AE. An abnormal test result determ ined to be an error does not require reporting as 
an AE.   
Evidence of product sensitization (the presence of donor anti -HLA antibodies absent prior to 
implant ) is not in itself considered an AE. The above criteria should also be utilized to determine 
if the sensitization qualifies as an AE.  
8.1.4. Adverse Events of Special Interest  (AESI)  
Certain AEs may require additional investigation to ensure appropriate information and data are 
captured to appropriately evaluate the clinical development of VC -02. These are considered 
adverse events of special interest (AESI) and may include but are not limited to:  
• AEs leading  to the unexpected or premature explantation  of VC-02-300 or sentinel units  
are considered  AESI . 
• AEs that result in early withdrawal from the study.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
74 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • Seve re hypoglycemic events  occurring after VC -[ADDRESS_1109992]  that additional da ta be collected for these  events.  
8.1.5. Period of Observation  and Reporting  
All AEs with a start date occurring between Visit 2 ( Week  -4) and through the last subject visit 
must be recorded on the CRF.  During the study, sites should query subjects on the status of  any 
ongoing AEs at subsequent clinic visits. Depending on the reported event, the Investigat or may 
need to follow -up on the status of AEs with the study subject  between visits  (e.g., phone , text, or 
email). At the conclusion of the trial, any ongoing AEs will be followed until at least [ADDRESS_1109993]’s participation 
in the mandatory, long-term follow -up study. Further details on how to report ongoing AEs 
spanning the period be tween the VC02- 101 protocol and follow -up study  will be outlined in the 
separate follow -up protocol.  
All AE reporting, including SAEs and S[LOCATION_003]Rs, will be carried out in accordance with applicable 
regulations.  
8.2. Serious Adverse Events (SAE) 
An SAE is any untoward medical occurrence meeting at least one of the following criteria : 
• Results in death;  
• Is life -threatening (immediate risk of death);  
• Requires in -patie nt hospi[INVESTIGATOR_1081];  
• Results in persistent or significant d isability/incapacity (substantial disruption of the ability 
to conduct normal life functions);  
• Results in congenital anomaly/birth defect;  
• Constitutes an Important Medical Event  in the opi[INVESTIGATOR_3755]/or Sponsor . 
Medical and scientific judg ment is exercised in determining whether an event is an important 
medical event.   An important medical event may not be immediately life threatening and/o r result 
in death or hospi[INVESTIGATOR_059]. However, if it is determined the event may jeopardize the subjec t or 
may require intervention to prevent one of the other S AE criteria , the important medical event 
should be reported as serious.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
75 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Based on the definition above, severe hypoglycemic events (SHE) may or may not be reported as 
SAEs and will be classified at the Investigator’s discretion. In all instances , SHEs are  to be 
recorded on the hypoglycemic event ( HE) CRF.  
AEs resulting in  hospi[INVESTIGATOR_17127] a hospi[INVESTIGATOR_804141]. Any 
formal a dmission (even if less than 24 hours) to a healthcare facility meets th ese criteria.  
Admission also includes transfer within the hospi[INVESTIGATOR_804142] e unit (e .g., from 
the psychiatric wing to a medical floor, medical floor to a coronary care unit, neurological floor to a tubercu losis unit).  
Hospi[INVESTIGATOR_4592]:  
• Rehabilitation facilities;  
• Hospi[INVESTIGATOR_4593];  
• Respi[INVESTIGATOR_4594] ( e.g., caregiver relief);  
• Skilled nursing facilities;  
• Nursing homes;  
• Emergency room visits ; 
• Outpatient surgical procedures . 
Hospi[INVESTIGATOR_804143] a precipi[INVESTIGATOR_2505], clinical AE is 
not in itself an SAE. Examples include:  
• Admission for treatment of a pre -existing condition not associated with the development 
of a new AE or with a worsening of the  preexisting condition (e.g., for work -up of 
persistent pre -treatment lab abnormality); 
• Social admission ( e.g., subject has no place to sleep);  
• Administrative admission (e.g., for yearly physical exam);  
• Protocol -specified admission during a study ( e.g., for a procedure required by [CONTACT_17143]);  
• Optional admission not associated with a precipi[INVESTIGATOR_804144] A E (e.g., for elective 
cosmetic surgery);  
• Hospi[INVESTIGATOR_4597] a medical AE; 
• Pre-planned treatments or surgical procedures sho uld be noted in the baseline medical 
history assessment and  documentation for an  individual subject.  
Diagnostic and therapeutic non- invasive and invasive procedures, such as surgery, should not be 
reported as AEs.  However, the medical condition for which t he procedure was performed should 
be reported if it meets the definition of an AE. For example, an acute appendi citis that begins 
during the AE reporting period should be reported as the AE , and the resulting appendectomy 
should be recorded as treatment of  the AE.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
76 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  8.2.1. Suspected, Unexpected Serious Adverse Reactions (S[LOCATION_003]R)  
A S[LOCATION_003]R is a serious adverse reaction which is thought to be causally related to the investigational 
product, surgical procedure, and/or immunosuppression regimen and which is unexpected to 
occur. Reporting of S[LOCATION_003]Rs to the Sponsor, all participating Investigators, the Ethics Committee, 
and to the Regulatory Authorities is mandatory in accordance with applicable regulations.  
Because of the limited shelf -life of the investigational product, the results of the [ADDRESS_1109994] be made immediately, irrespective of the extent of available AE informatio n.  
This t imeframe also applies to additional , new information (follow -up) on previously reported  
SAE reports as well as to the initial and follow -up reporting on cases of exposure during pregnancy 
and exposure via breastfeeding . 
In the rare event the Inve stigator does not become aware of the occurrence of an SAE immediately 
(e.g., a  study subject initially seeks treatment elsewhere), the Investigator  is to report the even t 
within [ADDRESS_1109995] death, a summary of available autopsy findings mus t be 
submi tted as soon as possible to the Sponsor . 
8.3. Reporting of Pregnancy 
For investigational products , an exposure during pregnancy ( referred to as Exposure in Utero 
[EIU]) occurs if a n enrolled female subject becomes, or is found to be, pregnant while in the study . 
In addition, if a male subject reports that his partner has become pregnant while he has had VC -[ADDRESS_1109996]’s partner becomes or is found to be pregnant during the study, the 
Investigator  must submit this information to the Sponsor  on an EIU Form . This must be done 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
77 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  within 24 hours of awareness of the event . The information submitted should include the 
anticipated date of delivery (s ee below for information related to termination of pregnancy). All 
confirmed EIU cases and f ollow -up information will be recorded in a Pregnancy R egistry.  
Follow -up is conducted to obtain pregnancy outcome information for all EIU reports. The 
Investigator  will follow the pregnancy until completion ( or until pregnancy termination) and notify 
the Sponsor  of the outcome as a follow -up to the initial EIU Form. In the case of a live birth , the 
structural integrity of the neonate  can be assessed at the time of birth. In the event of a termination, 
the reason(s) for termination should be specified, and, if clinically possible, the structural integrity 
of th e terminated fetus should be assessed by [CONTACT_4692] (unless pre -procedure test 
findings are conclusive for a congenital anomaly and the findings are reported).  
If the outcome of the pregnancy meets the criteria for an SAE (i.e., ectopic pregna ncy, spontaneous  
abortion, intraute rine fetal demise, neonatal death,  or congenital anomaly [in a liv e born, a 
terminated fetus , an intrauterine fetal demise, or a neonatal  death]), the Investigator  should follow 
the procedures for reporting SAEs. 
Additional information about pregnancy outc omes that are reported as SAEs include : 
• Spontaneous abortion includes miscarriage and missed abortion;  
• Neonatal deaths that occur within one month of birth should be reported, without  regard to 
causality, as SAEs.  
• Death of an infant olde r than one month should be reported as an SAE  if the Investigator  
assesses the infant death as related or possibl y related  to exposure to investigational 
product.  
Additional information regarding the exposure during pregnancy may be requested by [CONTACT_3786] .  Further fo llow-up of birth outcomes will be handled on a case -by-case basis ( e.g., 
follow -up on preterm infants to identify developmental delays).  In the case of paternal exposure, 
the investigator will provide the study subject with a Pregnant Partner Release of In formation Form 
to deliver to his partner. The Investigator must document on the EIU Form that the subje ct was 
given this letter to provide to his partner.  
8.4. Data Safety Monitoring Board (DSMB)  
An independent  Data Safety Monitoring Board (DSMB) will meet at s pecified times throughout 
the study to review the accumulation of  data. The DSMB will consist of at lea st [ADDRESS_1109997] . 
The approximate t iming of DSMB meetings are noted below:  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
78 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  • After a minimum of three (3) subjects  from Cohort  [ADDRESS_1109998] the DSMB to meet.  
The available cumulative data collected in all subjects from Cohort  1 up until that time will 
be evaluated by [CONTACT_4318] . Based on review of the available data, t he DSMB will make a 
recommendation on the enrollment of Cohort  2. The DSMB will not meet regularly durin g 
Cohort  1 unless there is a  related  AE that requires an independent DSMB review.  
• Quarterly during the first year of Cohort 2, and thereafter every three (3) to six (6) m onths 
until the last visit of the last Cohort [ADDRESS_1109999].  
8.5. Study Stoppi[INVESTIGATOR_804145], an ad -hoc meeting of the 
DSMB will be requested. The DSMB will review the  data and will recommend  stoppi[INVESTIGATOR_804146]:  
1. Two or more subjects have pronounce d immune responses to VC-02. 
2. Two or more subjects experiencing a NCI-CTCAE Grade 3 (severe)  treatment emergent 
adverse event (TEAE) in the same Medical  Dictionary for Regulatory Activities (MedDRA) 
system organ class (SOC) and preferred term (PT) considered to be possibly or probably 
related to the investigational product. TEAE is defi ned as an AE that starts on or after the date 
of implant surgery.  
3. After a minimum of eight weeks post -implantation, there are t wo or more subjects who each 
experienc e two or more  Severe H ypoglycemic E vents (SHE) over a 6- month period unrelated 
to anything other than VC -02. This assumes the SHE occurred despi[INVESTIGATOR_804147] .   
4. Two or more subjects develop S AEs deemed related to the implantation of VC- 02 itself ; 
examples of su ch events are no ted below:  
a. Development of an off -target cell growth (i.e., teratoma) within the unit which is noted on 
ultrasound and confirmed by [CONTACT_135789] .  
b. A related, severe, persistent, inflammatory response that does not resolve (e.g., severe site 
reactions, urtic aria, erythematous rash, anaphylaxis, acute respi[INVESTIGATOR_5448], 
swelling).  
5. Two or more subjects have an unexplained graft malfunction requiring explant . 
In addition to the se events, the DSMB can consider recommending a temporary dela y or hold on 
enrollment in the trial for events considered by [CONTACT_804195]- 02. The DSMB 
can also recommend  treatment continue for a shorter duration (i.e., less than the planned two years)  
or with a fewer number of implanted units . The DSMB can also recommend the Sponsor close the 
study at any time in response to any legitimate safety concerns. The Sponsor will communicate 
DSMB recommendations to each site in a timely fashion. Each site’s Ethics Committee  will make 
the ultimate dec ision to delay enrollment, modify treatment duration, or stop the study based on 
DSMB recommendations.   
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1110000]- explant in a long-term follow -up study (VC02- 201). 
9. CLINICAL MONITORING  
Routine m onitoring of investigative sites by [CONTACT_804196]. The 
purpose of these monitoring visits is to inspect the facilities an d various records of the trial.  
The study monitor is  responsible for inspecting electronic and/or online  case report forms (CRFs) 
at regular intervals throughout the study to verify adherence to the protocol . During site visits, the 
monitors will review source documents to confirm the data recorded on CRFs are accurate. The 
monitor will ensure completeness and accuracy of the data an d adherence to local regulations on 
the conduct of clinical research. The Investigator  and institution will allow study monitors direct 
access to source documents to perform this verification.  The Investigator  and site staff agree to 
cooperate with the monitor to ensure issues detected are approp riately addressed and resolved. It 
is important that the Investigator and relevant site personnel are available during the monitoring 
visits and possible audits or inspections by [CONTACT_1034], designee, or Regulatory Authorities and 
that sufficient time is devoted to the process. An associated monitoring plan will outline items to 
be monitored and the frequency of monitoring.  
10. STATISTICAL CONSIDERATIONS  
Methodology for the summarization and analysis  of the data collect ed in this trial are given here 
and further detailed  in a SAP,  which will be maintained by [CONTACT_1034] . The SAP may be written 
and approved prior to the Cohort  1 data cut -off (e.g., the last subject in Cohort  1 completing the 
Week  4 visit whose data is par t of the DSMB data review) , since this time -point will trigger a 
DSMB review of the accumulated data  and result in a recommendation for enrollment of Cohort  2.  
The study SAP  may modify what is outlined in the protocol; however, any major modifications of 
the endpoint s or their analyses will be reflected in a protocol amendment.  
The phrase “treatment group” is used in this section to denote the number of initially implanted 
VC-02-[ADDRESS_1110001] has a VC -02-300 unit explanted for any reason and remains in the 
study, then he/she will be included in the treatment group that is  described by [CONTACT_804197]-02-[ADDRESS_1110002] will be included in the “0 implanted VC -02-300 units” treatment group.  
10.1. Study Hypotheses 
As this is a f irst-in-human study, there are no statistical hypotheses being tested.   
10.2. Sample Size Considerations  
At least three ( 3) and up to approximate ly fifteen (15)  subjects will be enrolled in  Cohort  1.  
Approximately 60 subjects will be enrolled in Cohort  2, for a total enrollment of up to 75 subjects  
in both cohorts . 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY 2020 
80 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Sample size in Cohort 1 was empi[INVESTIGATOR_68151], based upon safety considerations and  data 
accumulated from previously performed ViaCyte clinical trials. A sample size of up to 15 subjects 
should allow for adequate assessment of Cohort 1 study objectives. 
A sample size of 60 subjects in Cohort 2 will enable staggered enrollment of cadres of subjects 
allowing for testing of alternate device configuration and/or surgical implant technique (e.g., 
pharmac ological intervention, implant site, etc.) in order to improve engraftment and cell survival 
outcomes. This approach will drive VC -02 engraftment optimization. 
Once the optimized device configuration and surgical implant technique is determined, a  sample 
size of 40 subjects implanted  
  
 
Since Cohort 1 has the primary objective of evaluating initia l safety and 
tolerability, these subjects will not contribute MMTT data for the Week  26 analysis. 
If the minimal level of detection for C -peptide is 0.20 ng/mL, this would give an AUC of 0.8 ng x 
hour/mL for the 4 -hour MMTT. A sample size of 40 subjects  
  
  
For the 2 -hour MMTT, a sample size of 40 subjects will provide  
  
 
 
10.3. Interim Analysis 
No decision -making interim analyses (e.g., for early stoppi[INVESTIGATOR_582413], or for 
modification to the planned enrollment) are planned. The DSMB will revie w all accumulated data 
when at least a minimum of three (3) Cohort [ADDRESS_1110003] s complete the Week  4 vis it, in order to make 
a recommendation on enrollment of  Cohort 2. In addition, a descriptive analysis may be produced 
when all subjects reach their Week  26 visit to support regulatory discussions. This report, if 
produced, will summarize key safety and effi cacy endpoints for these subjects.  
10.3.1. Safety Review 
To help assess specific safety events in this FIH study and/or to evaluate the implantation and 
explantati on techniques, the Sponsor or designee, Medical Monitor, and site surgeon(s)  and/or 
Investigator (s) w ill maintain close communication during Cohort 1. 
There will be an independent  DSMB.  Further information about the DSMB may be found in 
Section  8.4 of th is protocol as well as the DSMB C harter , including specific descriptions of the 
scope of the members' responsibilities and the processes and definitions used to review and  assess 
specific safety events.  
Additional safety event adjudication committees may be established as appropriate. As described above, individual committee charters will provide specific descriptions of the scope of 

ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1110004] in Cohort  2 passes Visit 1 1 (Week  26), cumulative data fr om all Cohort  [ADDRESS_1110005] , and the DSMB believes the safety data are 
appropriate, the Sponsor  may choose  to proceed to an End- of-Phase 2 (EoP2) meeting w ith the 
FDA to discuss next steps. 
The Sponsor will perform  a risk/benefit assessment at 9-[ADDRESS_1110006]’s data in order to determi ne whether that subject should continue taking chronic 
immu nosuppression and remain in the study or whether all units will be explanted. Factors 
evaluated include C -peptide concentration, histology from a sentinel device explanted at 
approximately nine (9)  months, change from baseline in average weekly insulin adm inistration, 
change from baseline in HbA1c, change from baseline in frequency of hypoglycemic events, 
change from baseline in Clarke Score, change from baseline in time -in--range, compliance with 
immunosuppression, as well as adverse events and other safet y findings. In cases where a subject 
is early terminated from the study as a result of the risk/benefit assessment, specific early termination visit procedures (i.e., the 4 -hour MMTT and safety ult rasound) will not need to be 
repeated if they were recently  performed (within the last 8 weeks).  
10.4. Analysis Details  
10.4.1. Analysis Populations  
The Full Analysis Set (FAS) is defined as all subjects from Cohort [ADDRESS_1110007] one VC-02-300 or sentinel unit  on Study Day  1. All 
efficacy summaries/analyses will be performed on the FAS.  Subjects will be summarized by 
[CONTACT_804198] . 
The Safety Analysis Set (SAS) will include all subjects from Cohort  [ADDRESS_1110008] characteristics such as gender, race, age, and baseline vital 
signs will be summarized. Pertinent medical history will also be summarized.  
10.4.3. Primary Saf ety Analysis  
Unless otherwise specified, the SAS ( for both Cohort  1 and Co hort 2 subjects who meet the SAS 
criteria) will be used for the primary safety summarizations.  Adverse events and SAEs will be 
summarized by [CONTACT_2946], by [CONTACT_926], and by [CONTACT_2073] . This will be done by [CONTACT_37821]. The summarization of AEs will focus on only those events that are TEAEs , but the AE 
listings will include all reported AEs regardless of when they started.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
82 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  Other safety data, such as vital sig ns and clinical laboratory data will be summarized by [CONTACT_804199].  Where appropriate, change from baseline in safety data will also be 
summarized in a similar manner.   
The number of subjects undergoing a premature VC- 02-300 unit explan t will be provided in a 
listing  which includes the reason for explantation (i.e., safety issue, malfunction, damaged, 
planned explant, etc .) 
10.4.4. Primary Efficacy Analysis  
Change from baseline to Week  26 in C-peptide AUC 0-4h following a n MMTT will be analyzed 
using analysis of co variance (AN COVA), with treatment group  as a factor  and baseline C -peptide 
AUC 0-4h as a covariate.  The FAS will be used to analyze the primary efficacy endpoint , with the 
ANCOVA performed within each Cohort . The output from the AN COVA will include the least 
squares mean (LSM) and standard error (SE) for each treatment group.  
10.4.5. Secondary Analyses  
Each of the secondary efficacy endp oints will be analyzed using an α = 0.05 level of significance.  
Given the large number of secondary effic acy endpoints, the p- values for these endpoints will be 
considered descriptive.  
[IP_ADDRESS]. Secondary Efficacy Analyses  
The FAS will be used to analyze the secondary efficacy endpoints, with the  analysis for each 
endpoint performed within each Cohort . Change from base line in C -peptide AUC 0-4h following an 
MMTT at Weeks 52 and 104 and change from bas eline in C -peptide AUC 0-2h following an MMTT 
at Weeks 16 , 26, 39, 52, 78, and 104 will be analyzed in a similar manner to the ANCOVA 
performed for change from baseline in C -peptide AUC 0-4h at Week  26, with the relevant baseline 
as the covariate.  
Change from baseline in frequency of hypoglycemic events (24- hour; daytime [start between 
6 a.m. – 12 a.m.]; nocturnal [start between 12 a.m. – 6 a.m.]) at Weeks 16, 26, 52, 78; change from 
baseline to Weeks 16, 26, 52, 78 and 104 in Clarke score; and change from baseline to Weeks 16,  
26, 52, 78 and 104 in average daily insulin dose in the seven days preceding th e clinic visit will be 
analyzed using ANCOVA, with treatment group  as a factor and the relevant baseline as a covariate.  
Time to onset of biological response of C -peptide following MMTT will be assessed using Kaplan -
Meier (KM) curves, with  the p- value from the logrank test also provided . 
The percent of subjects achieving a positive stimulated C -peptide (defined as > 0.2 ng/mL) after 
implant; the percent of subjects free of severe hypoglycemic events  from Week  16 to Weeks 20, 
26, 39, 52, 78 and 104; the per cent of subjects who achieve a 50% reduction in average weekly 
exogenous insulin dose from baseline to Weeks 16, 20, 26, 39, 52, 78, and 104; the percent of 
subjects who achieve exogenous insulin independence ; the percent of subjects who achieve 
exogenous insulin independence  and an HbA1c < 7.0% will each be analyzed using Fisher’s exact 
test.  The number and percent of subjects in each treatment group and the p -value from the Fisher’s 
test will be provided (at each timepoint, where appropr iate). 
Percent of  time spent with blood glucose values at various cut points at each scheduled visit will 
be summarized descriptively. The percentages and change from baseline percentages will be 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
83 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  summarized for each cut point (<54 mg/dL, ≥54 to <70 mg/dL, ≥70 mg/dL to ≤180 mg/dL, and 
>180 mg/dL ) and for each treatment group.  
[IP_ADDRESS]. Secondary Safety Analyses  
Unless otherwise specified, the SAS (both Cohort  1 and Cohort  2 subjects who meet the SAS 
criteria) will be used  to summarize seco ndary safety endpoints. For the secondary safety endpoint 
of immune response as measured by [CONTACT_804200], any subject 
who appears to be having an immune response will have all relevant data described in a clinical 
narrative . In addition, data of interest from the assays may be summarized by [CONTACT_14459].  
Changes in physical examinations will be summarized  by [CONTACT_14454].  
Non-diabetic concomitant medications will also be summa rized  by [CONTACT_6654].  
Finally, implantation site assessments will be summarized at each time- point post -implantation 
and each visit thereafter. For each site assessment symptom, the number of subjects with the 
symptom at that time -point wi ll be summarized  by [CONTACT_14454].  
11. SOURCE DOCUMENTS AND  ACCESS TO SOURCE DA TA / 
DOCUMENTS  
In compliance with ICH GCP guidelines, it is required that the Investigator  and institution permit 
authorized representatives of the Sponsor or designee, regulatory agenc y(s), and the Ethics 
Committee  direct access to review the subject’s original medical records for verification of study -
related procedures and data. Direct access includes examining, analyzing, verifying, and/or 
reproducing any records and reports that are  important for the evaluation of the study.   
12. SPONSOR AUDITS AND I NSPECTIONS BY [CONTACT_804201] l Protocol, Good Clinical Practice 
(GCPs) and applicable regulatory requirements, the Investiga tor and Institution should permit 
formal auditing by [CONTACT_804202], companies working with the Sponsor, and inspection by [CONTACT_112103]. The study site may be subject to review by [CONTACT_804203] . Inspection of the site’s facilities and review of study -related records may occur 
for any reason. 
The Investigator  and site staff agree to allow the auditors/inspectors to hav e direct access to sour ce 
documents and study records for review, being understood that the per sonnel is bound by 
[CONTACT_56520].  The Investigator and site staff will make every effort to help with the 
performance of the audits and inspections, giving access to all necessary facilities, data and 
documents. It is important that the Investigator  and all relevant personnel are available during the 
audits or inspections and that sufficient time is devoted to the process.  
If the Investigator  is notified of a future inspection by [CONTACT_12721], s/he will inform the 
Sponsor or designee and a uthorize the Sponsor to participate in this inspection. The Investigator  
will immediately communicate to the Sponsor any results and/or information ari sing from the 
inspections by [CONTACT_50756].  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
84 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  13. ETHICS/PROTECTION OF HUMAN SUBJECTS  
13.1. Ethical Standard  
The study will be conducted in accordance with legal and regulatory requirements, as well as the 
general principles set forth in the International  Ethical Guidelines for Biomedical Research 
Involving Human Subjects (Council for International Organizat ions of Medical Sciences 2002), 
Guidelines for GCP (ICH 1996), and the Declaration of Helsinki (World Medical Association 1996 & 2008).  
13.2. Ethics Committe es 
An Ethics Committee  must be constituted according to applicable requirements for each 
participating lo cation.  
It is the responsibility of the Investigator to have prospective, documented written approval of the 
study protocol, protocol amendments, informed consent documents, and other relevant documents, e.g., recruitment advertisements, if applicable, from the Ethics Committee . All correspondence 
with the Ethics Committe e should be retained in the Investigator  File. Copi[INVESTIGATOR_804148] s should be forwarded to the Sponsor . 
The Institution shall have no ability to alter, amend or modify the protocol. The only circumstance in which an amendment may be initiated without  Ethics Committee and Sponsor approval is where 
the change is necessary t o eliminate apparent immediate hazards to the subjects. In that event, the 
Investigator  must notify the E thics Committee and Sponsor in writing immediately after the 
implementation.  
13.3. Informed Consent Process  
The Investigator, or a person designated by [CONTACT_941] I nvestigator, will obtain written informed consent 
from each subject before any study- specific activity is  performed. The Investigator will retain the 
original of each subject’s signed consent document and any amendments to the consent document.  A copy of the signed consent form will be provided to the participant.  
The informed consent document must be in com pliance with ICH GCP, local regulatory 
requirements, and legal requirements. 
The informed consent document(s) used during the informed consent process must be reviewed 
and approved by [CONTACT_941] S ponsor  (prior to use), approved by [CONTACT_20601] , and availa ble for 
inspection. The Investigator must ensure that each study subject is fully informed about the nature 
and objectives of the study and possible ri sks associated with participation.  
13.4. Exclusion of Women, Minorities, and Children (Special Populations)  
Children will not be included in this trial. Each site will be encouraged to employ specific efforts 
to attract appropriate minority subjects and women. 
13.5. Subject Confidentiality  
All data will be coded by [CONTACT_804204].,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1110009] by 
[CONTACT_32819]. Documents that are not for submission to Sponsor (e.g., source documents) should 
be kept in strict confidence by [CONTACT_737].  See also Section  11. 
13.6. Reasons for Withdrawal  
Investigators will make reasonabl e efforts to keep enrolled subjects in the study. However, if a 
subject is removed from treatment, a termination visit must be performed. This would generally 
include all proced ures outlined in Visit  17 (Week  104) as well as the procedures outlined in foll ow-
up Visit 18 ( Week  105). Adverse events should be followed until their resolution.  
Subjects may withdraw from the trial at any time at their own request, or they may be withdrawn at any time at the discretion of the Investigator or Sponsor for safety or behavioral reasons. 
There are subject -specific criteria and product- related criterion that will necessitate withdrawal 
from the study.  
• After a minimum of eight weeks post -implan tation, the subject  experiences three or more  
Severe Hypoglycemic Events (SHE) o ver a six -month period unrelated to anything other 
than VC -02. This assumes the SHE occurred despi[INVESTIGATOR_804149] e dietary adjustments.  
• Subject has a new onset, off -target cell growth within the unit confirmed by a board-
certified pathologist as a teratoma and is considered  related to VC -02. 
• Subject appears to mount an immune or inflammatory response that puts the subject at risk 
for severe or serious immune reaction AEs. In this case, the Sponsor will assess the case 
fully (e.g., clinically and immune test results) and advise whether an explant of any units 
is advisable to facilitate continued participation . 
• Subject becomes pregnant  or in the Investigator’s opi[INVESTIGATOR_804150]- compliant with 
contraception requirements (see Section 5.4.5).  
• Due to the recommendation based upon the outcome of a risk/benefit assessment (see 
Section 10.3.2).  
• Implante d units appear to be damaged or malfunctioning (e.g., loc alized infections, 
damaged unit ) resulting in severe or serious AEs. Note:  In the case of a suspected 
malfunctioning or damaged unit , the Sponsor will assess the case fully and advise whether 
an expl ant of any units is advisable. E xplant of one VC -02-[ADDRESS_1110010] withdraws from the trial and also withdraws consent for disclosure 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1110011].  
It is recommended that three ( 3) attempts by [CONTACT_804205] ( 3) attempts by  [CONTACT_804206] . All attempts to contact [CONTACT_804207]’s medical record. Procedures will be put in place at each site to ensure that if a subject loses contact [CONTACT_804208], alternative measures will be utilized for the collection of 
information. This may include contact[CONTACT_804209], when appropriate, using subject location services. In a ll circumstances , every effort should be made  to 
document  the subject’s outcome, if possible, and to advise the subject to return to the clinic for 
explantation of the VC- 02-[ADDRESS_1110012] been discontinued from the main study prematurely (with products explant ed) will be rolled over into a  long- term,  follow -up trial. Those 
subjects may initiate any other therapy as needed to treat diabetes and any other concurrent medical conditions . 
Withdrawal due to AE should be distinguished from withdrawal due t o insufficient response and 
recorded on the appropriate AE CRF page. When a subject withdraws due to an SAE, the SAE must be reported in accordance with the reporting requirements defined in Section  8. The reason 
for discontinuation will be documented in the subject’s source records.  
For safety reasons, all early termination procedures (including explantation procedure) as described in Visit 17/ET and Visit [ADDRESS_1110013] those subjects to provide informat ion as per local requirements.  
The Investigator will schedule all remaining, active subjects as soon as reasonably possible for completion of the Visit 17 (ET) and Visit 18 procedures. These procedures should be completed 
as described for early withdrawal subjects in Section  13.6.1.  
13.8. Future Evaluation of Explanted U nits 
Evaluati on of the explanted units is previously described. However, evaluated units may  not be 
discarded , and there is the possibility of other future evaluation s.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- [ADDRESS_1110014] parties, 
except for authorized representatives of the Sponsor or appropriate regulatory authorities, without 
written permission from t he Sponsor . 
14.2. Data Capture Methods  
The Investigator  shall capture data in the form and manner required by [CONTACT_1034]. The 
Investigator has ultimate responsibility for the collection  and reporting of all clinical and safety 
data entered on the CRFs and any o ther data collection forms (e.g., source documents) and ensuring 
that they are accurate, authentic, or iginal, attributable, complete, consistent, legible, timely 
(contemporaneous), enduring, and available when required. The Investigator  or appropriate site  
personnel  must sign (electronica lly or hard copy) the CRF(s)  to attest that the data contained on 
the CRFs are true. Any correctio ns to entries made in the CRFs or source documents must be dated, 
initialed and explained (if necessary) and should not obscure the original entry.  
14.3. Types of D ata 
In most cases, the source documents (the first recording of the data) are the hospi[INVESTIGATOR_307]’s or the 
physician’s subject  chart , laboratory reports , etc. The data collected on the CRFs must match the 
source data.  Source documents also include , but are not l imited to,  the data captured by [CONTACT_804210], insulin dose logs, and hypoglycemia event entries. There 
may be cases where the CRF, or part of the CRF, may serve as a source document.  In these cases, 
a document should be  available at the Investigator ’s site as well as at the Sponsor and clearly 
identify those data that will be recorded in the CRF, and for which the CRF will stand as the source document.  
It is expected that laboratory data  (e.g., MMTT, CGM blood glucose da ta, ultrasound results ), 
traceable to a particular subject, wi ll be transmitted electronically to the study database in an 
ongoing manner during the study.  
14.4. Study Records Retention  
To enable evaluations and/or audits from regulatory authorities or the Sponsor and its designees , 
the Investigator agrees to keep records,  including the identity of all participating subjects 
(sufficient information to link records, e .g., CRFs and hospi[INVESTIGATOR_1097]), all original signed 
informed conse nt documents, copi[INVESTIGATOR_310890] s, safety reporting forms, source documents, and 
detailed reco rds of treatment disposition, and adequate documentation of relevant correspondence 
(e.g., letters, e -mails, meeting minutes, telephone calls , reports).  The records should be retained 
by [CONTACT_804211] (ICH) local 
regulations, or as specified in the Clinical Study Agreement (CSA), whichever is longer.  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
88 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  If the Investigator  becomes unable for any reason to continue to retain study rec ords for the 
required period (e .g., retirement, relocation), the Sponsor should be prospectively notified. The 
study records must be transferred to a designee acceptable to the Sponsor , such as another 
Investigator , another institution, or to an independent third party arranged by [CONTACT_1034] .  
The Investigator  must obtain the Sponsor’s written permission before disposing of any records.  
14.5. Protocol Deviations  
Every attempt to follow the protocol as written must be made. However, it is expected  there may 
be deviations resulting from circumstances beyond control  or unintentional oversights or mistakes.  
Any instance of a protocol -required test not being performed at the required time, or within the 
protocol -described time window, will constitute a protocol devi ation. These deviations will be 
documented by [CONTACT_804212]. Corrective actions will be put into 
place to prevent future occurrences of deviations, if possible. These deviations from the protocol 
must be docume nted at the sit e, and the Sponsor must be notified. Depending on the particular EC 
used at each site, notification of the EC may be warranted as well.  
15. DATA P ROTECTION  
The subject ’s protected healthcare information shall be treated in compliance with all ap plicable 
laws and regulations. When archiving or processing the protected healthcare information of  the 
subjects , the Institution, Investigator, Sponsor and designees shall take all appropriate measures to 
safeguard and prevent access to th ese data by [CONTACT_13159].  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
89 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  16. LITERATURE REFERENCE S 
Barton, F. B., Rickels, M. R., Alejandro, R., Hering, B. J., Wease, S., Naziruddin, B., et al. 
(2012, July). Improvement in Outcomes of Clinical Islet Transplantation: 1999- 2010. 
Diabet es Care, 35 , 1436- 1445. 
Brauker, J. H., Shults, M. C., & Tapsak, M. A. (2004, March). Patent No. US 6,702,857 B2. 
[LOCATION_002].  
Cantarelli, E., & Pi[INVESTIGATOR_77878], L. (2011). Alternative Transplantation Sites for Pancreatic Islet 
Grafts. Current Diabetes Reports, 11, 364- 374. 
CITR Coordinating Center. (2011). CITR 7th Annual Report. Rockville: The EMMES 
Corporation.  
Drukker, M., Katchman, H., Katz, G., Even- Tov Friedman, S., Shezen, E., Hornstein, E., et al. 
(2006). Human Embryonic Stem Cells and Their Differentiated Derivativ esAre Less 
Susceptible to Immune Rejection Than Adult Cells. Stem Cells, 24 , 221 -229. 
Gold, A., Macleod, K., & Frier , B. (1994, July). Frequency of Severe Hypoglycemia in Patients 
With Type I Diabetes With Impaired Awareness of Hypoglycemia. Diabetes Care,  17(7), 
697-703. 
Leitao, C. B., Tharavanij, T., Cure, P., Pi[INVESTIGATOR_163926], A., Baidal, D. A., Ricordi, C., et al. (2008, 
November). Restoration of Hypoglycemia Awareness After Islet Transplantation. 
Diabetes Care, 31 (11), 2113- 2115. 
Ryan, E., Shandro, T., Green, K ., Paty, B., Senior, P., Bigam, D., et al. (2004). Assessment of the 
Severity of Hypoglycemia and Glycemic Lability in Type 1 Diabetic Subjects 
Undergoing Islet Transplantation. Diabetes, 53(4), 955- 962. 
Wahren, J., Kallas, A., & Simas, A. A. (2012, April) . The Clinical Potential of C -Peptide 
Replacement in Type 1 Diabetes. Diabetes, 61(4), 61:761- 771. 
 
 
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
90 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared  17. SUPPLEMENTS AND APPE NDICES  
Appendix  1: Clarke Hypoglycemia Unawareness Survey 
 
1. Check the category that best describes you: (check one only)  
 
 I always h ave symptom s when my blood sugar is low  A 
 I sometimes have symptoms when my blood sugar is low  R 
 I no longer have symptoms when my blood sugar is low  R 
 
2. Have you lost some of the symptoms that used to occur when your blood sugar was low?  
 
 Yes R 
 No A 
 3. In the past six months how often have you had moderate hypoglycemia epi[INVESTIGATOR_1841]? (Epi[INVESTIGATOR_54815], disoriented, or lethargic and were unable to treat yourself)  
 
 Never  A 
 Once or twice  R 
 Every other month  R 
 Every month  R 
 More than once a month  R 
 
4. In the past year how often have you had severe hypoglycemic epi[INVESTIGATOR_1841]? (Epi[INVESTIGATOR_80723] a seizure and needed glucagon or intravenous glucose)  
 
 Never  A  [ADDRESS_1110015] you had readings < 70 mg /dL (3.8 mmol/L) with 
symptoms?  
ViaCyte Inc.,  Confidential           Amendment # 9 – Version 8.0 
Protocol #VC02- 101  18 MAY  2020 
91 
Property of ViaCyte, Inc. - strictly confidential and not intended to be shared   
 Never   1 time/week   4 to 5 times/week  
 1 to 3 times   2 to 3 times/week   Almost daily  
 
6. How often in the last month have you had readings < 70 mg /dL (3.8 mmol/L) without 
symptoms?  
 
 Never   1 time/week   4 to 5 times/week  
 1 to 3 times   2 to 3 times/week   Almost daily  
 
If answer to question 5 < answer to question 6  R 
If answer to qu estion 6 ≤ answer to question 5  A 
 7. How low does your blood sugar need to go before you feel symptoms?  
 
 60-69 mg/dL,                  3.3 - 3.8 mmol/L A 
 50-59 mg/dL;                  2.8 – 3.3 mmol/L A 
 40-49 mg/dL;                  2.2 – 2.7 mmol/L R 
 less th an 40  mg/dL         less than 2.2  mmol/L R 
 8. To what extent can you tell by [CONTACT_54859]?  
 
 Never  R 
 Rarely  R 
 Sometimes  R 
 Often  A 
 Always  A 
 Final score: Total Number of “R” responses: ________ 
 
Interpretation: Four or more “R” responses = reduced awareness; 2 or fewer “R” responses= aware  